Patent Publication Number: US-2016244728-A1

Title: Culture method for pluripotent stem cells and kit and medium for culture of pluripotent stem cells used therein

Description:
CROSS-REFERENCE TO RELATED APPLICATIONS 
     This application is a continuation application of International Application No. PCT/JP2014/073948, filed Sep. 10, 2014, the disclosure of which is incorporated herein by reference in its entirety. Further, this application claims priority from Japanese Patent Application No. 2013-187441, filed Sep. 10, 2013, the disclosure of which is incorporated herein by reference in its entirety. 
    
    
     BACKGROUND OF THE INVENTION 
     1. Field of the Invention 
     The present invention relates to a culture method for pluripotent stem cells and to a kit and a medium for culture of pluripotent stem cells used in the culture method. 
     2. Description of the Related Art 
     For the purpose of the recovery of functions of damaged tissues, various regenerative medical techniques are being developed. Among these, a large number of techniques relating to totipotent or pluripotent stem cells of primates, particularly, human beings that is ultimately aimed at the regeneration of tissues has been reported. Especially, induced pluripotent stem cells (iPS cells) have an advantage in that these cells lessen ethical issues because they are induced from somatic cells unlike embryonic stem cells. 
     In a case where the totipotent or pluripotent stem cells (both will be collectively simply referred to as “pluripotent stem cells” in the present invention) of primates are cultured, the cells need to be kept undifferentiated for a long period of time. For culturing the undifferentiated pluripotent stem cells for a long period of time, generally, feeder cells such as mouse fibroblasts are used. 
     However, it has been pointed out that the use of heterogeneous animal-derived feeder cells such as mouse fibroblasts leads to a likelihood that foreign substances such as heterogeneous animal-derived antigenic substances may be mixed into the culture solution. Therefore, in a case where the totipotent or pluripotent stem cells are used for medical purposes or for the purposes equivalent to medical purposes, the cells need to be cultured without feeder cells. 
     In consideration of the circumstances described above, cell-adhesive materials functioning as the feeder cells are being developed. For example, Nature Biotechnology, 2001, Vol. 19, pp. 971-974 discloses that human embryonic stem cells kept undifferentiated are successfully cultured by using matrix gel which is a component extracted from mouse sarcoma as a substituent for feeder cells. 
     JP2001-17183A discloses a feeder cell-free cellular composition containing growing primordial cells of primates, and discloses, as a preferred embodiment, a cellular composition further containing an extracelluar matrix. JP2010-29186A discloses a cell culture substrate in which a plasma-polymerized cell culture surface is additionally coated with a coating solution containing an extracellular matrix protein at a predetermined concentration and an aqueous solvent. JP2010-29186A describes that the cell culture substrate has excellent adhesiveness helpful to avoid the differentiation of embryonic stem cells. 
     Biomaterials, 2010, November; Vol. 31(32), pp. 8281-8288 and Nature biotechnology, 2010, Vol. 28, No. 6, pp. 606-610 disclose a recombinant peptide or a synthetic peptide having a partial sequence of vitronectin that makes a contribution to long-term culture of embryonic stem cells. Specifically, the above documents disclose a sequence consisting of the 1 st  to 52 nd  amino acids of natural vitronectin (see Biomaterials, 2010, November; Vol. 31(32), pp. 8281-8288) and a sequence consisting of the 41 st  to 52 nd  amino acids of natural vitronectin including an RGD sequence (see Nature biotechnology, 2010, Vol. 28, No. 6, pp. 606-610) respectively. It is known that these peptides make it possible to avoid a likelihood of intermixing of antigenic substances because they are non-biological samples and can be excellently produced in an industrial manner. 
     Furthermore, regarding a medium for culture of pluripotent stem cells in an undifferentiated state, for example, JP2013-510567A discloses ascorbic acid, basic fibroblast growth factor (bFGF), a serum-free medium which does not contain a heterogeneous component. 
     SUMMARY OF THE INVENTION 
     JP2001-17183A, JP2010-29186A, Nature Biotechnology, 2001, Vol 19, pp. 971-974, Biomaterials, 2010, November; Vol. 31(32), pp. 8281-8288, and Nature biotechnology, 2010, Vol. 28, No. 6, pp. 606-610 disclose materials that can replace the feeder cells, and JP2013-510567A discloses a medium that is suitable for culture of pluripotent stem cells. However, there is a demand for a better culture method having excellent cell culture performance for pluripotent stem cells. 
     Accordingly, objects of the present invention are to provide a culture method for pluripotent stem cells that is excellent in cell culture performance for pluripotent stem cells, particularly, a cell growth ability for pluripotent stem cells, and to provide a kit and a medium for culture of pluripotent stem cells that are used in the culture method. 
     In order to achieve the aforementioned objects, the inventors of the present invention continued intensive research on the culture method for pluripotent stem cells. As a result, they obtained knowledge that if pluripotent stem cells are cultured using a polypeptide, which includes the amino acid sequence of human vitronectin or a predetermined partial amino acid sequence of human vitronectin, and a medium containing an ascorbic acid derivative in a predetermined amount, the cell culture performance, particularly, the cell growth ability for the pluripotent stem cells becomes excellent. Based on the knowledge, the inventors accomplished the present invention. 
     That is, a culture method for pluripotent stem cells of the present invention includes obtaining a polypeptide-coated culture surface by applying a polypeptide onto a cell culture surface of a support and culturing pluripotent stem cells by seeding the pluripotent stem cells onto the polypeptide-coated culture surface by using a medium in which the content of an ascorbic acid derivative is equal to or greater than 1.5 mmol/L (mM), in which the polypeptide is (a) a polypeptide having an amino acid sequence represented by SEQ ID NO: 1, (b) a polypeptide having an amino acid sequence, which shares identity of equal to or higher than 80% with the amino acid sequence represented by SEQ ID NO: 1, and having culture performance for pluripotent stem cells, or (c) a polypeptide having an amino acid sequence, which is formed by the deletion, substitution, or addition of one amino acid or several amino acids (preferably 1 to 5 amino acids) in SEQ ID NO: 1, and having culture performance for pluripotent stem cells. 
     Furthermore, another culture method for pluripotent stem cells of the present invention is a method including obtaining a polypeptide-coated culture surface by applying a polypeptide onto a cell culture surface of a support and culturing pluripotent stem cells by seeding the pluripotent stem cells onto the polypeptide-coated cell culture surface by using a medium in which the content of an ascorbic acid derivative is equal to or greater than 1.5 mmol/L (mM), in which the polypeptide is (d) a polypeptide consisting of 40 to 450 amino acid residues and including (1) a first region including at least one amino acid sequence selected from the group consisting of an amino acid sequence represented by CSYYQSC (SEQ ID NO: 2) and an amino acid sequence represented by RGD and (2) a second region including (2-i) an amino acid sequence which is represented by PRPSLAKKQRFRHRNRKGYRSQRGHSRGRNQN (SEQ ID NO: 3), (2-ii) an amino acid sequence which shares identity of equal to or higher than 80% with the amino acid sequence represented by SEQ ID NO: 3 and exhibits adsorbability with respect to the cell culture surface of the support, or (2-iii) an amino acid sequence which is formed by the addition, substitution, or deletion of one amino acid residue or several amino acid residues (preferably 1 to 5 amino acid residues) in the amino acid sequence represented by SEQ ID NO: 3 and exhibits adsorbability with respect to the cell culture surface of the support. 
     A kit for culture of pluripotent stem cells of the present invention is a kit including (a) a polypeptide having an amino acid sequence represented by SEQ ID NO: 1, (b) a polypeptide having an amino acid sequence, which shares identity of equal to or higher than 80% with the amino acid sequence represented by SEQ ID NO: 1, and having culture performance for pluripotent stem cells, or (c) a polypeptide having an amino acid sequence, which is formed by the deletion, substitution, or addition of one amino acid or several amino acids (preferably 1 to 5 amino acids) in SEQ ID NO: 1, and having cell culture performance for pluripotent stem cells and a medium in which the content of an ascorbic acid derivative is equal to or greater than 1.5 mmol/L (mM). 
     Furthermore, another kit for culture of pluripotent stem cells of the present invention is a kit including a polypeptide and a medium in which the content of an ascorbic acid derivative is equal to or greater than 1.5 mmol/L (mM), in which the polypeptide is (d) a polypeptide consisting of 40 to 450 amino acid residues and including (1) a first region including at least one amino acid sequence selected from the group consisting of an amino acid sequence represented by CSYYQSC (SEQ ID NO: 2) and an amino acid sequence represented by RGD and (2) a second region including (2-i) an amino acid sequence which is represented by PRPSLAKKQRFRHRNRKGYRSQRGHSRGRNQN (SEQ ID NO: 3), (2-ii) an amino acid sequence which shares identity of equal to or higher than 80% with the amino acid sequence represented by SEQ ID NO: 3 and exhibits adsorbability with respect to a cell culture surface of a support, or (2-iii) an amino acid sequence which is formed by the deletion, substitution, or addition of one amino acid residue or several amino acid residues (preferably 1 to 5 amino acid residues) in the amino acid sequence represented by SEQ ID NO: 3 and exhibits adsorbability with respect to the cell culture surface of the support. 
     The medium of the present invention is a medium in which the content of an ascorbic acid derivative is equal to or greater than 1.5 mmol/L (mM). 
     According to the present invention, it is possible to provide a culture method for pluripotent stem cells that is excellent in cell culture performance for pluripotent stem cells, particularly, a cell growth ability for pluripotent stem cells and to provide a kit and a medium for culture of pluripotent stem cells that are used in the culture method. 
    
    
     
       BRIEF DESCRIPTION OF THE DRAWINGS 
         FIG. 1  is a graph showing the results of a test performed to check how well each polypeptide according to the present invention is adsorbed onto the surface of a culture plate. 
         FIG. 2  is a graph showing growth curves of iPS cells using each polypeptide according to the present invention. 
         FIG. 3A  shows a morphic image (left side) and a magnified image (right side) of an iPS cell colony cultured on each polypeptide according to the present invention. 
         FIG. 3B  shows a morphic image (left side) and a magnified image (right side) of an iPS cell colony cultured on each polypeptide according to the present invention. 
         FIG. 3C  shows a morphic image (left side) and a magnified image (right side) of an iPS cell colony cultured on each polypeptide according to the present invention. 
         FIG. 3D  shows a morphic image (left side) and a magnified image (right side) of an iPS cell colony cultured on each polypeptide according to the present invention. 
         FIG. 3E  shows a morphic image (left side) and a magnified image (right side) of an iPS cell colony cultured on each polypeptide according to the present invention. 
         FIG. 4A  shows an image of iPS cells stained with DAPI (left side) and an image of iPS cells stained with NANOG (right side) that are captured in a case where the iPS cells are cultured on each polypeptide according to the present invention. 
         FIG. 4B  shows an image of iPS cells stained with DAPI (left side) and an image of iPS cells stained with NANOG (right side) that are captured in a case where the iPS cells are cultured on each polypeptide according to the present invention. 
         FIG. 4C  shows an image of iPS cells stained with DAPI (left side) and an image of iPS cells stained with NANOG (right side) that are captured in a case where the iPS cells are cultured on each polypeptide according to the present invention. 
         FIG. 4D  shows an image of iPS cells stained with DAPI (left side) and an image of iPS cells stained with NANOG (right side) that are captured in a case where the iPS cells are cultured on each polypeptide according to the present invention. 
         FIG. 4E  shows an image of iPS cells stained with DAPI (left side) and an image of iPS cells stained with NANOG (right side) that are captured in a case where the iPS cells are cultured on each polypeptide according to the present invention. 
     
    
    
     DESCRIPTION OF THE PREFERRED EMBODIMENTS 
     Hereinafter, embodiments of the present invention will be specifically described. 
     &lt;Polypeptide&gt; 
     The polypeptide according to the present invention is (a) a polypeptide having an amino acid sequence represented by SEQ ID NO: 1, (b) a polypeptide having an amino acid sequence, which shares identity of equal to or higher than 80% with the amino acid sequence represented by SEQ ID NO: 1, and having culture performance for pluripotent stem cells, or (c) a polypeptide having an amino acid sequence, which is formed by the deletion, substitution, or addition of one amino acid or several amino acids in SEQ ID NO: 1, and having culture performance for pluripotent stem cells. SEQ ID NO: 1: 
     
       
         
           
               
            
               
                 SEQ ID NO: 1: 
               
               
                 DQESCKGRCTEGFNVDKKCQCDELCSYYQSCCTDYTAECKPQVTRGDVFT 
               
               
                   
               
               
                 MPEDEYTVYDDGEEKNNATVHEQVGGPSLTSDLQAQSKGNPEQTPVLKPE 
               
               
                   
               
               
                 EEAPAPEVGASKPEGIDSRPETLHPGRPQPPAEEELCSGKPFDAFTDLKN 
               
               
                   
               
               
                 GSLFAFRGQYCYELDEKAVRPGYPKLIRDVWGIEGPIDAAFTRINCQGKT 
               
               
                   
               
               
                 YLFKGSQYWRFEDGVLDPDYPRNISDGFDGIPDNVDAALALPAHSYSGRE 
               
               
                   
               
               
                 RVYFFKGKQYWEYQFQHQPSQEECEGSSLSAVFEHFAMMQRDSWEDIFEL 
               
               
                   
               
               
                 LFWGRTSAGTRQPQFISRDWHGVPGQVDAAMAGRIYISGMAPRPSLAKKQ 
               
               
                   
               
               
                 RFRHRNRKGYRSQRGHSRGRNQNSRRPSRATWLSLFSSEESNLGANNYDD 
               
               
                   
               
               
                 YRMDWLVPATCEPIQSVFFFSGDKYYRVNLRTRRVDTVDPPYPRSIAQYW 
               
               
                   
               
               
                 LGCPAPGHL 
               
            
           
         
       
     
     Herein, “having culture performance for pluripotent stem cells” means the polypeptide has a growth activity for pluripotent stem cells. Whether or not the polypeptide has the growth activity can be evaluated in the following method, for example. Onto a cell culture surface onto which the polypeptide is adsorbed, pluripotent stem cells are seeded at a cell density of 250 cells/well, the pluripotent stem cells are cultured for 8 days, and then nonadhesive cells are washed off with PBS. At this time, whether or not the number of adhesive cells present is equal to or greater than 2,500 cells/well (10 times the number of seeded cells) is checked to evaluate the growth activity. 
     Herein, the number of adhesive cells can be quantified by a method in which the activity of alkaline phosphatase expressed by the pluripotent stem cells is quantified, an MTT test, or the like. 
     The full-length polypeptide represented by SEQ ID NO: 1 constituted with 495 amino acid residues is vitronectin. In the present invention, vitronectin means human vitronectin. It has been confirmed that natural vitronectin is a sugar protein having a sugar chain in a portion of the sequence thereof. 
     Hereinafter, in the resent specification, the polypeptide according to the present invention will be referred to as a “polypeptide for culture” in some cases. 
     In the present specification, the term “step” includes not only an independent step, but also a step that cannot be clearly distinguished from other steps as long as the intended object thereof is achieved. 
     In the present specification, a range of numerical values represented by using “to” means a range which includes numerical values listed before and after “to” as a minimum value and a maximum value respectively. 
     In the present specification, in a case where there is a plurality of substances corresponding to each component in a composition, unless otherwise specified, the amount of each component in the composition means the total amount of the plurality of substances present in the composition. 
     In the specification of the present application, “one amino acid or several amino acids” means “1 to 5 amino acids”. 
     In the present specification, “homogeneous” means a human being, and “heterogeneous” means an animal other than a human being. 
     In the present specification, an amino acid residue in an amino acid sequence is designated by one letter (for example, “G” for a glycine residue) or by three letters (for example, “Gly” for a glycine residue) in some cases as widely known in the field of the related art. 
     In the present invention, unless otherwise specified, “%” relating to an amino acid sequence of a polypeptide is based on the number of amino acid (or imino acid) residues. 
     In the present specification, the expression such as “the corresponding amino acid residue” used for a specific amino acid residue in an amino acid sequence means an amino acid residue in an amino acid sequence that is in the same position as a specific amino acid residue in another amino acid sequence as a standard when sequence alignment are performed on two or more contrasting amino acid sequences by a method known in the field of the related art in consideration of insertion, deletion, and substitution so as to maximize the number of amino acid residues identical to each other. 
     In the present specification, “identity” relating to an amino acid sequence can refer to a value calculated by using a BLAST package (see Ausubel et al., 1999 Short Protocols in Molecular Biology, 4th Ed—Chapter 18). For example, to share identity of equal to or higher than 80% with SEQ ID NO: 1 means that a value of Max. Identities in BLAST is equal to or greater than 80. 
     The polypeptide (b) is preferably a polypeptide having an amino acid sequence, which shares identity of equal to or higher than 90% (that is, 90% to 100%) with the amino acid sequence represented by SEQ ID NO: 1, and having culture performance for pluripotent stem cells, and more preferably a polypeptide having an amino acid sequence, which shares identity of equal to or higher than 95% (that is, 95% to 100%) with the amino acid sequence represented by SEQ ID NO: 1, and having culture performance for pluripotent stem cells. 
     The polypeptide (c) is preferably a polypeptide having an amino acid sequence, which is formed by the deletion, substitution, or addition of 1 to 5 amino acids in SEQ ID NO: 1, and having culture performance for pluripotent stem cells. 
     The polypeptide according to the present invention is preferably (a1) a polypeptide including an amino acid sequence represented by SEQ ID NO: 1, (b1) a polypeptide including an amino acid sequence, which shares identity of equal to or higher than 80% (that is, 80% to 100%) with the amino acid sequence represented by SEQ ID NO: 1, and having culture performance for pluripotent stem cells, or (c1) a polypeptide including an amino acid sequence, which is formed by the deletion, substitution, or addition of one amino acid or several amino acids in SEQ ID NO: 1, and having culture performance for pluripotent stem cells. 
     Herein, the polypeptide (b1) is preferably a polypeptide including an amino acid sequence, which shares identity of equal to or higher than 90% (that is, 90% to 100%) with the amino acid sequence represented by SEQ ID NO: 1, and having culture performance for pluripotent stem cells, and more preferably a polypeptide including an amino acid sequence, which shares identity of equal to or higher than 95% (that is, 95% to 100%) with the amino acid sequence represented by SEQ ID NO: 1, and having culture performance for pluripotent stem cells. 
     In addition, the polypeptide (c1) is preferably a polypeptide including an amino acid sequence, which is formed by the deletion, substitution, or addition of one amino acid or several amino acids and preferably 1 to 5 amino acids in SEQ ID NO: 1, and having culture performance for pluripotent stem cells. 
     For example, as the polypeptide according to the present invention, Vitronectin-XF (manufactured by Primorigen Biosciences) can be preferably used. 
     The polypeptide according to the present invention is preferably a polypeptide having an amino acid sequence formed by partially or completely deleting at least one of an amino acid sequence, which consists of the 1 st  to 44 th  amino acid residues in the amino acid sequence of human vitronectin, and an amino acid sequence, which consists of the 379 th  to 449 th  amino acid residues in the amino acid sequence of human vitronectin, from the amino acid sequence (SEQ ID NO: 1) of human vitronectin. The polypeptide according to the present invention is more preferably a polypeptide having an amino acid sequence formed by partially or completely deleting an amino acid sequence, which consists of the 1 st  to 44 th  amino acid residues in the amino acid sequence of human vitronectin, and an amino acid sequence, which consists of the 379 th  to 449 th  amino acid residues in the amino acid sequence of human vitronectin, from the amino acid sequence of human vitronectin. The polypeptide according to the present invention is even more preferably a polypeptide having an amino acid sequence formed by partially deleting an amino acid sequence, which consists of the 1 st  to 44 th  amino acid residues in the amino acid sequence of human vitronectin, and partially deleting an amino acid sequence, which consists of the 379 th  to 449 th  amino acid residues in the amino acid sequence of human vitronectin, from the amino acid sequence of human vitronectin. 
     Furthermore, the polypeptide according to the present invention is preferably “a polypeptide having an amino acid sequence which consists of the 62 nd  to 478 th  amino acid residues in the amino acid sequence of human vitronectin”, “a polypeptide having an amino acid sequence, which shares identity of equal to or higher than 80% (that is, 80% to 100%) with the amino acid sequence consisting of the 62 nd  to 478 th  amino acid residues in the amino acid sequence of human vitronectin, and having culture performance for pluripotent stem cells”, or “a polypeptide having an amino acid sequence, which is formed by the deletion, substitution, or addition of one amino acid or several amino acids in the amino acid sequence consisting of the 62 nd  to 478 th  amino acid residues in the amino acid sequence of human vitronectin, and having culture performance for pluripotent stem cells”. The polypeptide according to the present invention is more preferably “a polypeptide consisting of an amino acid sequence which consists of the 62 nd  to 478 th  amino acid residues in the amino acid sequence of human vitronectin”. For example, as the polypeptide according to the present invention, VTN-N (manufactured by Life Technologies) can be preferably used. 
     Another polypeptide according to the present invention is the following polypeptide (d). 
     (d) A polypeptide consisting of 40 to 450 amino acid residues and including (1) a first region including at least one amino acid sequence selected from the group consisting of an amino acid sequence represented by CSYYQSC (SEQ ID NO: 2) and an amino acid sequence represented by RGD and (2) a second region including (2-i) an amino acid sequence which is represented by PRPSLAKKQRFRHRNRKGYRSQRGHSRGRNQN (SEQ ID NO: 3), (2-ii) an amino acid sequence which shares identity of equal to or higher than 80% with an amino acid sequence represented by SEQ ID NO: 3 and exhibits adsorbability with respect to a cell culture surface of a support, or (2-iii) an amino acid sequence which is formed by the deletion, substitution, or addition of one amino acid residue or several amino acid residues in the amino acid sequence represented by SEQ ID NO: 3 and exhibits adsorbability with respect to the cell culture surface of the support. 
     In order to have the culture performance for pluripotent stem cells, the polypeptide for culture needs to exhibit “cell adhesiveness with respect to pluripotent stem cells” and “adsorbability with respect to a cell culture surface of a support”. Herein, the support is a site of a culture vessel that has a surface to which the polypeptide according to the present invention is applied at the time of performing cell culture by using the culture method of the present invention. 
     In the polypeptide (d) according to the present invention, the first region including a predetermined amino acid sequence has excellent cell adhesiveness. Therefore, the polypeptide (d) enables cells, particularly, pluripotent stem cells to grow excellently. The polypeptide (d) according to the present invention having such an amino acid sequence enables pluripotent stem cells to grow for a long period of time while maintaining the undifferentiated state of the cells. 
     In addition, the second region including a predetermined sequence makes a contribution to the adsorbability with respect to the cell culture surface of the support. The polypeptide (d) according to the present invention having such an amino acid sequence exhibits excellent adhesiveness with respect to the cell culture surface of the support. Further, since the second region is included in the polypeptide together with the first region, the pluripotent stem cells can be grown for a long period of time while maintaining the undifferentiated state of the cells, without being exfoliated from the cell culture surface of the support for the duration of culture. Furthermore, the polypeptide (d) according to the present invention enables the pluripotent stem cells which are being cultured in the undifferentiated state to grow while inhibiting exfoliation of the cells from the cell culture surface of the support, and can improve the handleability in the culture operation. 
     As a result, it is possible to obtain a polypeptide which accelerates the growth of pluripotent stem cells in the undifferentiated state, does not require a treatment for fixing the polypeptide to the cell culture surface of the support through chemical bonding, and can be industrially produced. 
     In addition, the polypeptide (d) according to the present invention having the first and second regions can eliminate the risk of the intermixing of an antigenic substance and an infection source unlike the natural vitronectin, and can retain the performance equivalent to the performance of the natural human vitronectin, that is, the adhesiveness with respect to the pluripotent stem cells, the cell growth properties, and the undifferentiated state maintainability. 
     Furthermore, the pluripotent stem cells cultured in the presence of the polypeptide (d) according to the present invention having the first and second regions (preferably in the absence of a heterogeneous animal-derived component or the like) can substantially completely eliminate or significantly reduce a likelihood that a foreign substance such as an antigenic substance derived from a sample or the like may be mixed into the cells. Therefore, when the pluripotent stem cells cultured by the aforementioned culture method are used for medical purposes or for purposes equivalent to medical purposes, sufficient safety can be ensured. 
     Furthermore, according to the culture method using the polypeptide (d) of the present invention having the first and second regions, pluripotent stem cells can be cultured at lower cost by a simple operation. Therefore, the culture method can make a great contribution when being used for the medical purposes and in the field of research. 
     The first region includes at least one amino acid sequence selected from the group consisting of an amino acid sequence represented by SEQ ID NO: 2 and an RGD sequence. 
     The amino acid sequence represented by SEQ ID NO: 2 corresponds to seven amino acid residues consisting of the 25 th  to 31 st  amino acids residues in the amino acid sequence of vitronectin. Furthermore, the RGD sequence is a cell adhesive motif which corresponds to three amino acid residues consisting of the 45 th  to 47 th  amino acid residues in the amino acid sequence of vitronectin. All of these amino acid sequences are sequences positioned relatively on the N-terminal side of natural vitronectin. Presumably, these amino acid sequences may exhibit adhesiveness with respect to the undifferentiated pluripotent stem cells and thus enable the pluripotent stem cells kept undifferentiated to grow. Therefore, compared to a polypeptide including none of these amino acid sequences, a polypeptide including all of these amino acid sequences is excellent in the cell adhesiveness and has a better cell growth ability. 
     Two cysteine residues in the amino acid sequence represented by SEQ ID NO: 2 may be cross-linked with each other. In this way, a high-order structure is formed in the amino acid sequence represented by SEQ ID NO: 2, and the adhesiveness with respect to the pluripotent stem cells tend to be improved. 
     Here, “enabling the pluripotent stem cells to grow in an undifferentiated state” means that the pluripotent stem cells retains differentiation potency for the duration of culture. Whether or not the pluripotent stem cells are in an undifferentiated state can be evaluated by a known method. For example, it can be evaluated by the methods known to those in the related art, such as expression of molecular markers (measuring the expression of SSEA-4 and/or Oct-4 by means of flow cytometry, immunostaining by using Oct-4 and/or NANOG, and the like), checking the pluripotent differentiation by in-vitro experiment, and checking the formation of teratoma resulting from the transplantation of the cells into an immunodeficient mouse. Whether or not the pluripotent stem cells are growing should be checked through a common method by means of visual observation using various microscopes, by means of a technique using a test for reactivity such as ALP activity, flow cytometery, or the like, or by means of other techniques. In the present invention, the duration for which the pluripotent stem cells are cultured in a state of retaining the differentiation potency can be set to be, for example, one month, although the duration varies with the culture conditions and the state of the pluripotent stem cells. 
     The first region in the polypeptide for culture should include any one of the amino acid sequences selected from the group consisting of the amino acid sequence represented by SEQ ID NO: 2 and the RGD sequence. From the viewpoint of the cell adhesiveness and the cell growth properties, the first region in the polypeptide for culture preferably includes both the amino acid sequence represented by SEQ ID NO: 1 and the RGD sequence. 
     The first region may have an amino acid sequence other than the amino acid sequence represented by SEQ ID NO: 2 and the RGD sequence. From the viewpoint of the cell adhesiveness and the cell growth properties of the first region, examples of such an amino acid sequence include (1a) an amino acid sequence consisting of the 1 st  to 24 th  amino acid residues of the amino acid sequence of human vitronectin represented by SEQ ID NO: 1, (1b) an amino acid sequence consisting of the 48 to 55 amino acid residues in the amino acid sequence of human vitronectin represented by SEQ ID NO: 1, (1c) an amino acid sequence consisting of the 32 nd  to 44 th  amino acid residues in the amino acid sequence of human vitronectin represented by SEQ ID NO: 1, and a combination of these. Each of the amino acid sequences (1a) to (1c) may have an amino acid sequence in which one amino acid or several amino acids and preferably 1 to 5 amino acids are deleted, substituted, or added, within a range that does not impair the cell adhesiveness and the cell growth properties of the first region. Furthermore, each of the amino acid sequences (1a) to (1c) may have an amino acid sequence which shares identity of equal to or higher than 80% (that is, 80% to 100%), preferably equal to or higher than 90% (that is, 90% to 100%), and even more preferably equal to or higher than 95% (that is, 95% to 100%) with each of the amino acid sequences (1a) to (1c). 
     The first region may include at least one amino acid sequence selected from the group consisting of the amino acid sequences (1a) to (1c), in addition to the amino acid sequence represented by SEQ ID NO: 2 and the RGD sequence. From the viewpoint of the cell adhesiveness and the cell growth properties, it is preferable that the first region includes both the amino acid sequence represented by SEQ ID NO: 2 and the RGD sequence and further includes an amino acid sequence which consists of the 1 st  to 55 th  amino acid residues of the amino acid sequence represented by SEQ ID NO: 1, an amino acid sequence similar to the aforementioned amino acid sequence, or a partial amino acid sequence thereof. It is also preferable that the first region includes both the amino acid sequence represented by SEQ ID NO: 2 and the RGD sequence and further includes an amino acid sequence consisting of the 25 to 47 amino acid residues of the amino acid sequence represented by SEQ ID NO: 1, an amino acid sequence similar to the aforementioned amino acid sequence, or a partial amino acid sequence thereof. 
     Examples of amino acid sequences preferable for the first region include (1-i) an amino acid sequence which consists of the 1 st  to 55 th  amino acid residues in the amino acid sequence represented by SEQ ID NO: 1, (1-ii) an amino acid sequence which shares identity of equal to or higher than 80% (that is, 80% to 100%), preferably equal to or higher than 90% (that is, 90% to 100%), and more preferably equal to or higher than 95% (that is, 95% to 100%) with an amino acid sequence consisting of the amino acid sequence (1-i) and exhibits cell adhesion ability with respect to pluripotent stem cells, and (1-iii) an amino acid sequence which consists of an amino acid sequence formed by the deletion, substitution, or addition of one amino acid or several amino acids and preferably 1 to 5 amino acids in the amino acid sequence (1-i) and exhibits cell adhesion ability with respect to pluripotent stem cells. 
     From the viewpoint of the cell adhesiveness and the growth properties, the first region can consist of 3 to 60 amino acid residues and preferably can consist of 10 to 55 amino acid residues. 
     The second region may include an amino acid sequence consisting of 32 amino acid residues represented by SEQ ID NO: 3. From the viewpoint of ease of purifying the polypeptide for culture, the second region is preferably a polypeptide including the amino acid sequence represented by SEQ ID NO: 3. The amino acid sequence represented by SEQ ID NO: 3 is included in a portion of a hemopexin-like domain II positioned on the C-terminal side of the natural vitronectin and corresponds to a heparin binding domain consitituted with the 342 nd  to 373 th  amino acid residues of the amino acid sequence represented by SEQ ID NO: 1. Hereinafter, the amino acid sequence represented by SEQ ID NO: 3 will be referred to as a heparin binding domain in some cases. 
     Presumably, the polypeptide (d) for culture may exhibit adsorbability with respect to a cell culture surface of a support because the polypeptide (d) has the heparin binding domain. For this reason, the polypeptide (d) for culture enables the undifferentiated pluripotent stem cells to grow for a long period of time while maintaining the undifferentiated state. 
     Furthermore, because the polypeptide (d) for culture includes the heparin binding domain, the hydrophilicity of the polypeptide for culture is ensured, and the hydrophobic aggregation of the polypeptide tends to be inhibited. As a result, it is easy to purify the polypeptide for culture, and the production efficiency can be improved. 
     Herein, “exhibiting adsorbability with respect to a cell culture surface of a support” means that the amino acid sequence can be physically adsorbed onto the cell culture surface of a target culture vessel (hereinafter, simply referred to as a “culture surface” in some cases) without chemically reacting with the culture surface. Whether or not the polypeptide exhibits adsorbability with respect to the cell culture surface of the support can be evaluated by the following method, for example. In the method, a solution containing the polypeptide is added in an amount of 200 pmol/cm 2  to a plasma-treated culture vessel made of polystyrene, and the culture vessel is left to stand for 2 hours at 37° C. and then washed twice with a phosphate buffer solution. Thereafter, whether or not the amount of the polypeptide remaining on the surface of the culture dish is equal to or greater than 10 pmol/cm 2  is checked to evaluate the adsorbability of the polypeptide. 
     The amount of the polypeptide remaining on the surface of the culture dish can be measured by an Enzyme-Linked Immunosorbent Assay (ELISA) method in which the amount of the polypeptide binding to antibodies recognizing the polypeptide is determined or by a method in which the adsorbed polypeptide is hydrolyzed and the amount of the generated amino acid is determined by HPLC or the like. 
     The heparin binding domain may share identity of equal to or higher than 80% (that is, 80% to 100%) with the amino acid sequence represented by SEQ ID NO: 3. The identity may be preferably equal to or higher than 90% (that is, 90% to 100%), and more preferably equal to or higher than 95% (that is, 95% to 100%). Furthermore, the heparin binding domain may be an amino acid sequence which enables the pluripotent stem cells to grow in an undifferentiated state and exhibits adsorbability with respect to the cell culture surface of the support. 
     The heparin binding domain may include an amino acid sequence formed by the deletion, substitution, or addition of one amino acid residue or several amino acid residues and preferably 1 to 5 amino acid residues in the amino acid sequence represented by SEQ ID NO: 3. Furthermore, the heparin binding domain may be an amino acid sequence which exhibits adsorbability with respect to the cell culture surface of the support. 
     The polypeptide (d) for culture should include the first and second regions, and the relative position thereof is not particularly limited. In the polypeptide (d) for culture, the first region is preferably positioned on the N-terminal side of the second region. 
     The polypeptide (d) for culture having the first and second regions consists of 40 to 450 amino acid residues. If the number of the amino acid residues is equal to or greater than 40, the cell adhesiveness, the cell growth properties, or the adsorbability with respect to the cell culture surface of the support becomes excellent. In contrast, if the number of the amino acid residues is equal to or less than 450, the cell adhesiveness, the cell growth properties, and the adsorbability with respect to the cell culture surface of the support are further exhibited, and the protein molecules can be inhibited from being agglomerated, cross-linked, or aggregated. From the viewpoint of making it difficult for the protein molecules to be aggregated, the number of amino acid residues constituting the polypeptide (d) for culture is preferably equal to or greater than 80, more preferably equal to or greater than 90, and even more preferably equal to or greater than 100. Furthermore, the number of amino acid residues constituting the polypeptide (d) for culture is preferably equal to or less than 400, more preferably equal to or less than 250, even more preferably equal to or less than 170, and still more preferably equal to or less than 150. Any of the aforementioned upper limits may be combined with any of the aforementioned lower limits. For example, the polypeptide (d) for culture preferably consists of 40 to 400 amino acid residues, more preferably consists of 80 to 250 amino acid residues, even more preferably consists of 80 to 150 amino acid residues, and still more preferably consists of 100 to 150 amino acid residues. 
     From the viewpoint of preventing the hydrophobic aggregation, it is preferable that the polypeptide (d) for culture has a GRAVY value of −2.0 to −0.95. The GRAVY value (Kyte J., Doolittle R. F. (1982), J. Mol. Biol, 157: 105-132) represents the total average of a degree of hydrophobicity of the polypeptide. The greater the GRAVY value, the higher the degree of hydrophobicity. If the GRAVY value is equal to or less than −0.95, the occurrence of the hydrophobic aggregation tends to be easily inhibited. In contrast, if the GRAVY value is equal to or greater than −2.0, the polypeptide tend to be easily adsorbed onto the cell culture surface of the support, the undifferentiated cells tend to grow easily, and the adsorbability and the cell growth properties tend to be improved as the GRAVY value increases. In view of accomplishing both the inhibition of the aggregation and the adsorbability or the cell growth properties, the GRAVY value of the polypeptide is more preferably −1.70 to −0.975, and even more preferably −1.60 to −1.10. The smaller the number of the amino acid residues, the more the aggregation tends to occur. Therefore, in a case of a polypeptide consisting of 80 to 170 amino acid residues, in view of accomplishing both the inhibition of the aggregation and the adsorbability or the cell growth properties, the GRAVY value is preferably −1.70 to −0.975 and more preferably −1.60 to −1.10. 
     The GRAVY value can be adjusted by increasing or decreasing the proportion of a hydrophobic amino acid (for example, Trp, Tyr, Phe, Leu, Ile, Val, or Met) in the sequence or by increasing or decreasing the number of amino acid residues in the sequence. 
     It is preferable that the polypeptide (d) for culture further has an amino acid sequence other than the first and second regions, in addition to the first and second regions. From the viewpoint of sufficiently exhibiting the cell adhesiveness and the adsorbability with respect to the cell culture surface of the support, the polypeptide for culture preferably further includes the amino acid sequence represented by SEQ ID NO: 1, that is, a partial sequence of the amino acid sequence of human vitronectin. In this way, the polypeptide for culture can obtain properties close to the properties of the human vitronectin, for example, excellent adhesiveness and growth properties for the pluripotent stem cells. 
     From the viewpoint of the cell adhesiveness and the cell growth properties of the polypeptide for culture, the adsorbability with respect to the cell culture surface of the support, or the inhibition of aggregation, the partial amino acid sequence of the human vitronectin that may be include in the polypeptide (d) for culture preferably includes at least one region selected from the group consisting of the following third and fourth regions. 
     (3) A third region including an amino acid sequence selected from an amino acid sequence, which consists of the 56 th  to 341 st  amino acid residues in the amino acid sequence represented by SEQ ID NO: 1, and a partial amino acid sequence thereof; and 
     (4) a fourth region including an amino acid sequence selected from an amino acid sequence, which consists of the 374 th  to 459 th  amino acid residues in the amino acid sequence represented by SEQ ID NO: 1, and a partial amino acid sequence thereof. 
     As the third region, it is possible to select (3a) an amino acid sequence, which consists of the 56 th  to 341 st  amino acid residues in the amino acid sequence represented by SEQ ID NO: 1, or a partial amino acid sequence thereof, (3b) an amino acid sequence, which consists of the 269 th  to 341 st  amino acid residues in the amino acid sequence represented by SEQ ID NO: 1, or a partial amino acid sequence thereof, (3c) an amino acid sequence, which consists of the 274 th  to 341 st  amino acid residues in the amino acid sequence represented by SEQ ID NO: 1, or a partial amino acid sequence thereof, or (3d) an amino acid sequence, which consists of the 294 th  to 341 st  amino acid residues in the amino acid sequence represented by SEQ ID NO: 1, or a partial amino acid sequence thereof, because the above amino acid sequences tend to inhibit the hydrophobic aggregation at the time of preparing the polypeptide. With the amino acid sequences (3a) to (3d), the hydrophobic aggregation tends to be able to be mitigated by reducing the number of amino acid residues. It is particularly preferable to select the amino acid sequence (3d) because the hydrophobic aggregation tends to be able to be more reliably inhibited. 
     It is preferable that the polypeptide (d) further includes the third region consisting of one of the following amino acid sequences (3a-i) to (3a-iii). 
     (3a-i) An amino acid sequence, which consists of the 56 th  to 341 st  amino acid residues in the amino acid sequence represented by SEQ ID NO: 1, or a partial amino acid sequence thereof; 
     (3a-ii) an amino acid sequence which shares identity of equal to or higher than 80% (that is, 80% to 100%), preferably equal to or higher than 90% (that is, 90% to 100%), and more preferably equal to or higher than 95% (that is, 95% to 100%) with the amino acid sequence (3a-i) or a partial amino acid sequence thereof; and 
     (3a-iii) an amino acid sequence which is formed by the deletion, substitution, or addition of one amino acid or several amino acids and preferably 1 to 5 amino acids in the amino acid sequence (3a-i) or a partial amino acid sequence thereof. 
     It is also preferable that the polypeptide (d) further include a third region consisting of one of the following amino acid sequences (3b-i) to (3b-iii). 
     (3b-i) An amino acid sequence, which consists of the 269 th  to 341 st  amino acid residues in the amino acid sequence represented by SEQ ID NO: 1, or a partial amino acid sequence thereof; 
     (3b-ii) an amino acid sequence which shares identity of equal to or higher than 80% (that is, 80% to 100%), preferably equal to or higher than 90% (that is, 90% to 100%), and more preferably equal to or higher than 95% (that is, 95% to 100%) with the amino acid sequence (3b-i) or a partial amino acid sequence thereof; and 
     (3b-iii) an amino acid sequence which is formed by the deletion, substitution, or addition of one amino acid or several amino acids and preferably, 1 to 5 amino acids in the amino acid sequence (3b-i) or a partial amino acid sequence thereof. 
     From the viewpoint of the adsorbability with respect to the culture dish, for the fourth region, it is possible to select an amino acid sequence, which consists of the 374 th  to 459 th  amino acid residues in the amino acid sequence represented by SEQ ID NO: 1, or a partial amino acid sequence thereof, to select an amino acid sequence which consists of the 374 th  to 409 th  amino acid residues in the amino acid sequence represented by SEQ ID NO: 1, or a partial amino acid sequence thereof, or to select an amino acid sequence, which consists of the 374 th  to 379 th  amino acid residues in the amino acid sequence represented by SEQ ID NO: 1, or a partial amino acid sequence thereof. 
     Among these, an amino acid sequence, which consists of the 374 th  to 379 th  amino acid residues in the amino acid sequence represented by SEQ ID NO: 1, or a partial amino acid sequence thereof is preferable, because such an amino acid sequence makes it possible to obtain the adsorbability with respect to the culture dish and makes it easy to inhibit the hydrophobic aggregation at the time of preparing the polypeptide. By reducing the number of amino acids selected, the hydrophobic aggregation tends to be mitigated. 
     It is preferable that the polypeptide (d) further includes a fourth region consisting of one of the following amino acid sequences (4a-i) to (4a-iii). 
     (4a-i) An amino acid sequence, which consists of the 374 th  to 459 th  amino acid residues in the amino acid sequence represented by SEQ ID NO: 1, or a partial amino acid sequence thereof; 
     (4a-ii) an amino acid sequence which shares identity of equal to or higher than 80% (that is, 80% to 100%), preferably equal to or higher than 90% (that is, 90% to 100%), and more preferably equal to or higher than 95% (that is, 95% to 100%) with the amino acid sequence (4a-i) or a partial amino acid sequence thereof; and 
     (4a-iii) an amino acid sequence which is formed by the deletion, substitution, or addition of one amino acid or several amino acids, preferably, 1 to 5 amino acids in the amino acid sequence (4a-i) or a partial amino acid sequence thereof. 
     It is also preferable that the polypeptide (d) further includes a fourth region including one of the one of the following amino acid sequences (4b-i) to (4b-iii). 
     (4b-i) An amino acid sequence, which consists of the 374 th  to 409 th  amino acid residues in the amino acid sequence represented by SEQ ID NO: 1, or a partial amino acid sequence thereof; 
     (4b-ii) an amino acid sequence which shares identity of equal to or higher than 80% (that is, 80% to 100%), preferably equal to or higher than 90% (that is, 90% to 100%), and more preferably equal to or higher than 95% (that is, 95% to 100%) with the amino acid sequence (4b-i) or a partial amino acid sequence thereof; and 
     (4b-iii) an amino acid sequence which is formed by the deletion, substitution, or addition of one amino acid or several amino acids, preferably, 1 to 5 amino acids in the amino acid sequence (4b-i) or a partial amino acid sequence thereof. 
     In addition, it is also preferable that the polypeptide (d) further include the fourth region including one of the following amino acid sequences (4c-i) to (4c-iii). 
     (4c-i) An amino acid sequence, which consists of the 374 th  to 379 th  amino acid residues in the amino acid sequence represented by SEQ ID NO: 1, or a partial amino acid sequence thereof; 
     (4c-ii) an amino acid sequence which shares identity of equal to or higher than 80% (that is, 80% to 100%), preferably equal to or higher than 90% (that is, 90% to 100%), and more preferably equal to or higher than 95% (that is, 95% to 100%) with the amino acid sequence (4c-i) or a partial amino acid sequence thereof; and 
     (4c-iii) an amino acid sequence which is formed by the deletion, substitution, or addition of one amino acid or several amino acids, preferably, 1 to 5 amino acids in the amino acid sequence (4c-i) or a partial amino acid sequence thereof. 
     The partial amino acid sequence of the amino acid sequence constituting the third and fourth regions means an amino acid sequence constituted with three or more consecutive amino acid residues among a predetermined range of amino acid residues. The number of amino acid residues of the partial amino acid sequence should be selected within a range that does not exceed the aforementioned total number of amino acid residues of the polypeptide (d) for culture. 
     By including the third region, the polypeptide (d) for culture tends to obtain an advantage of improving the adsorbability with respect to the culture dish. Furthermore, by including the fourth region, the polypeptide for culture tends to obtain an advantage of further improving the adsorbability with respect to the culture dish. The polypeptide for culture may have one of the third and fourth regions. 
     The GRAVY value of the polypeptide (d) for culture is preferably adjusted by increasing or decreasing the number of amino acid residues in the amino acid sequences constituting the third and fourth regions or by the substitution, deletion, addition, or the like of the amino acid residues, because then the GRAVY value can be easily adjusted. Particularly, the GRAVY value of the polypeptide (d) for culture is more preferably adjusted by adjusting the length of the amino acid sequence constituting the third region. 
     Among the amino acid residues constituting the amino acid sequence represented by SEQ ID NO: 1, the 56 th  to 131 st  amino acid residues, the 56 th  to 268 th  amino acid residues, the 269 th  to 273 th  amino acid residue, or the 50 th  to 293 th  amino acid residues may not be included in the polypeptide (d) for culture. Presumably, an amino acid sequence consisting of the above amino acid residues may not make a contribution to the performance of the polypeptide (d) for culture with respect to the pluripotent stem cells. Therefore, a sequence suitable for the adsorption of the polypeptide onto the culture dish is selected. 
     In a case where the third region includes an amino acid residue corresponding to a cysteine residue of the sequence represented by SEQ ID NO: 1, the third region may have an amino acid residue other than the cysteine residue in the position of the cysteine residue. It is preferable that the third region has an amino acid residue other than the cysteine residue because then intramolecular cross-linking or intermolecular cross-linking caused by the cysteine residue can be prevented. The amino acid residue substituting the cysteine residue is not particularly limited, and preferred examples thereof include a serine residue, an alanine residue, a glycine residue, and the like. Among these, a serine residue or an alanine residue are preferable because these have a structure similar to that of cysteine. 
     The polypeptide for culture may have any additional amino acid residues other than the aforementioned amino acid residues within a range that does not impair the cell adhesiveness and the adsorbability with respect to the cell culture surface of the support. Examples of the sequence consisting of any other amino acid residues described above include an additional sequence added for easily preparing the polypeptide for culture by a recombination technique. Examples of the additional sequence include a methionine residue on the N-terminal side, a GPLG sequence on the N-terminal side, a tag sequence (for example, glutathione S-transferase (GST), a FLAG tag, or a His tag), a linker sequence (for example, GGGS (SEQ ID NO: 40), GGGGS (SEQ ID NO: 41), or GGGGGS (SEQ ID NO: 42) which can be added so as to be positioned between the respective regions, and the like. 
     The polypeptide for culture can be manufactured by an amino acid synthesis technique or a gene recombination technique known to those in the related art. 
     Specifically, in a case where the polypeptide for culture of the present invention is obtained by the gene recombination technique, first, a gene encoding a target amino acid sequence is obtained, and the obtained gene is incorporated into an expression vector, thereby preparing a recombinant expression vector. Thereafter, by introducing the obtained recombinant expression vector into an appropriate host, a transformant is prepared. By culturing the obtained transformant in an appropriate medium, an intended polypeptide is produced. Therefore, by collecting the intended polypeptide from the culture by a common method, the polypeptide according to the present invention can be obtained. 
     From the viewpoint of the cell growth properties and the ability to grow the undifferentiated pluripotent stem cells in the undifferentiated state, and the like, the polypeptide for culture is preferably a polypeptide (A) which consists of 80 to 450 amino acid residues and includes (1) a first region consisting of an amino acid sequence consisting of the 25 th  to 47 th  amino acid residues of the amino acid sequence represented by SEQ ID NO: 1, (2) a second region, which consists of an amino acid sequence consisting of the 342 nd  to 373 rd  amino acid residues of the amino acid sequence represented by SEQ ID NO: 1, and at least one region selected from the group consisting of the following third and fourth regions: (3) a third region consisting of an amino acid sequence, which consists of the 269 th  to 341 st  amino acid residues of the amino acid sequence represented by SEQ ID NO: 1, or a partial amino acid sequence thereof, and (4) a fourth region consisting of an amino acid sequence, which consists of the 374 th  to 459 th  amino acid residues of the amino acid sequence represented by SEQ ID NO: 1, or a partial amino acid sequence thereof. 
     Furthermore, from the viewpoint of the cell growth properties, the ability to grow the undifferentiated pluripotent stem cells in the undifferentiated state, and the like, the polypeptide for culture is preferably a polypeptide (B) which consists of 100 to 450 amino acid residues and includes (1) a first region consisting of an amino acid sequence (including the amino acid sequence represented by SEQ ID NO: 2 and the RGD sequence) consisting of the 1 st  to 55 th  amino acid residues of the amino acid sequence represented by SEQ ID NO: 1, (2) a second region (heparin binding domain) consisting of an amino acid sequence, which consists of the 342 nd  to 373 rd  amino acid residues of the amino acid sequence represented by SEQ ID NO: 3, and at least one region selected from the group consisting of the following third and fourth regions: (3) a third region consisting of an amino acid sequence, which consists of the 269 th  to 341 st  amino acid residues of the amino acid sequence represented by SEQ ID NO: 1, or a partial amino acid sequence thereof, and (4) a fourth region consisting of an amino acid sequence, which consists of the 374 th  to 459 th  amino acid residues of the amino acid sequence represented by SEQ ID NO: 1, and a partial amino acid sequence thereof. 
     The polypeptide (A) or (B) is preferably a polypeptide having a GRAVY value of −2.0 to −0.95. 
     The polypeptide (A) preferably consists of 80 to 250 amino acid residues. 
     The polypeptide (A) is more preferably a polypeptide which has a GRAVY value of −2.0 to −0.95 and consists of 80 to 250 amino acid residues. 
     The polypeptide (A) is even more preferably a polypeptide which has a GRAVY value of −1.70 to −0.975 and consists of 80 to 250 amino acid residues. 
     The polypeptide (A) or (B) preferably consists of 100 to 250 amino acid residues. 
     The polypeptide (A) or (B) is more preferably a polypeptide which has a GRAVY value of −2.0 to −0.95 and consists of 100 to 250 amino acid residues. 
     The polypeptide (A) or (B) is even more preferably a polypeptide which has a GRAVY value of −1.70 to −0.975 and consists of 100 to 250 amino acid residues. 
     The polypeptide (A) or (B) is still more preferably a polypeptide which has a GRAVY value of −1.70 to −0.975 and consists of 100 to 170 amino acid residues. 
     Examples of the polypeptide for culture are shown below, but the present invention is not limited thereto. 
     
       
         
           
               
               
             
               
                 TABLE 1 
               
               
                   
               
               
                   
                 SEQ ID 
               
               
                 Amnio acid sequence 
                 No. 
               
               
                   
               
             
            
               
                 
                   
                     
                     
                         
                         
                     
                   
                 
                  4 
               
               
                 
                   
                     
                     
                         
                         
                     
                   
                 
                   
               
               
                 
                   
                     
                     
                         
                         
                     
                   
                 
                   
               
               
                 
                   
                     
                     
                         
                         
                     
                   
                 
                   
               
               
                 
                   
                     
                     
                         
                         
                     
                   
                 
                   
               
               
                 
                   
                     
                     
                         
                         
                     
                   
                 
                  5 
               
               
                 
                   
                     
                     
                         
                         
                     
                   
                 
                   
               
               
                 
                   
                     
                     
                         
                         
                     
                   
                 
                  6 
               
               
                 
                   
                     
                     
                         
                         
                     
                   
                 
                   
               
               
                 
                   
                     
                     
                         
                         
                     
                   
                 
                  7 
               
               
                 
                   
                     
                     
                         
                         
                     
                   
                 
                   
               
               
                 
                   
                     
                     
                         
                         
                     
                   
                 
                  8 
               
               
                 
                   
                     
                     
                         
                         
                     
                   
                 
                   
               
               
                 
                   
                     
                     
                         
                         
                     
                   
                 
                   
               
               
                 
                   
                     
                     
                         
                         
                     
                   
                 
                  9 
               
               
                 
                   
                     
                     
                         
                         
                     
                   
                 
                   
               
               
                 
                   
                     
                     
                         
                         
                     
                   
                 
                   
               
               
                 
                   
                     
                     
                         
                         
                     
                   
                 
                   
               
               
                 
                   
                     
                     
                         
                         
                     
                   
                 
                   
               
               
                 
                   
                     
                     
                         
                         
                     
                   
                 
                 10 
               
               
                 
                   
                     
                     
                         
                         
                     
                   
                 
                   
               
               
                 
                   
                     
                     
                         
                         
                     
                   
                 
                   
               
               
                 
                   
                     
                     
                         
                         
                     
                   
                 
                 11 
               
               
                 
                   
                     
                     
                         
                         
                     
                   
                 
                   
               
               
                 
                   
                     
                     
                         
                         
                     
                   
                 
                   
               
               
                 
                   
                     
                     
                         
                         
                     
                   
                 
                 12 
               
               
                 
                   
                     
                     
                         
                         
                     
                   
                 
                   
               
               
                 
                   
                     
                     
                         
                         
                     
                   
                 
                   
               
               
                 
                   
                     
                     
                         
                         
                     
                   
                 
                 13 
               
               
                 
                   
                     
                     
                         
                         
                     
                   
                 
                   
               
               
                 
                   
                     
                     
                         
                         
                     
                   
                 
                   
               
               
                 
                   
                     
                     
                         
                         
                     
                   
                 
                   
               
               
                 
                   
                     
                     
                         
                         
                     
                   
                 
                 38 
               
               
                 
                   
                     
                     
                         
                         
                     
                   
                 
                   
               
               
                 
                   
                     
                     
                         
                         
                     
                   
                 
               
               
                   
               
            
           
         
       
     
     Examples of polypeptides preferred as the polypeptide according to the present invention include (d1) a polypeptide having an amino acid sequence which is represented by one of SEQ ID NO: 4 to SEQ ID NO: 23, SEQ ID NO: 38, and SEQ ID NO: 39, (d2) a polypeptide having an amino acid sequence, which shares identity of equal to or higher than 80% (that is, 80% to 100%), more preferably equal to or higher than 90% (that is, 90% to 100%), and even more preferably equal to or higher than 95% (that is, 95% to 100%) with the amino acid sequence represented by one of SEQ ID NO: 4 to SEQ ID NO: 23, SEQ ID NO: 38, and SEQ ID NO: 39, and having culture performance for pluripotent stem cells, and (d3) a polypeptide having an amino acid sequence, which is formed by the deletion, substitution, or addition of one amino acid or several amino acids, preferably, 1 to 5 amino acids in the amino acid sequence represented by one of SEQ ID NO: 4 to SEQ ID NO: 23, SEQ ID NO: 38, and SEQ ID NO: 39, and having culture performance for pluripotent stem cells. 
     The polypeptide according to the present invention is more preferably (d4) a polypeptide consisting of an amino acid sequence which is represented by one of SEQ ID NO: 4 to SEQ ID NO: 23, SEQ ID NO: 38, and SEQ ID NO: 39, (d5) a polypeptide consisting of an amino acid sequence, which shares identity of equal to or higher than 80% (that is, 80% to 100%), more preferably equal to or higher than 90% (that is, 90% to 100%), and even more preferably equal to or higher than 95% (that is, 95% to 100%) with the amino acid sequence represented by one of SEQ ID NO: 4 to SEQ ID NO: 23, SEQ ID NO: 38, and SEQ ID NO: 39, and having culture performance for pluripotent stem cells, or (d6) a polypeptide consisting of an amino acid sequence, which is formed by the deletion, substitution, or addition of one amino acid or several amino acids, preferably, 1 to 5 amino acids in the amino acid sequence represented by one of SEQ ID NO: 4 to SEQ ID NO: 23, SEQ ID NO: 38, and SEQ ID NO: 39, and having culture performance for pluripotent stem cells. 
     &lt;Culture Method for Pluripotent Stem Cells&gt; 
     The culture method for pluripotent stem cells of the present invention includes obtaining a cell culture surface coated with the polypeptide for culture by applying the polypeptide according to the present invention to a cell culture surface of a support (hereinafter, referred to as a culture surface preparation step), and culturing pluripotent stem cells by seeding the pluripotent stem cells onto the culture surface coated with the polypeptide for culture by using a medium in which the content of an ascorbic acid derivative is equal to or greater than 1.5 mmol/L (mM) (hereinafter, referred to as a culture step). 
     In the culture method of the present invention, for the culture of pluripotent stem cells, a polypeptide having an amino acid sequence of vitronetin or an amino acid sequence derived from vitronectin is combined with a medium in which the content of an ascorbic acid derivative is equal to or greater than 1.5 mmol/L (mM). In this way, the pluripotent stem cells can more efficiently grow. 
     The pluripotent stem cells according to the present invention are pluripotent stem cells of an animal that belongs to primates. Specifically, the pluripotent stem cells include embryonic stem cells (ES cells), induced pluripotent stem cells (iPS cells), somatic stem cells, cells from inner cell mass of fertilized eggs, early embryonic cells, and the like. As the pluripotent stem cells, one kind of these cells may be used singly, or if necessary, two or more kinds thereof may be used by being mixed together. The iPS cells include the cells described in Nature, 2007, Jul. 19; Vol. 448, pp. 313-317; Cell, 2006, Aug. 25; Vol. 126(4), pp. 663-676 and cells similar to the above cells. 
     Examples of the pluripotent stem cells preferably used in the present invention include iPS cells. 
     Examples of the animal that belongs to primates include a human being, a monkey, a gorilla, and the like. The animal that belongs to primates is preferably a human being congeneric with the polypeptide for culture. As long as a component or a substance used in the present invention is a component or a substance derived from an animal that belongs to primates, it can be preferably used in the present invention as a component or a substance derived from a homogeneous animal. 
     In the medium according to the present invention, the content of an ascorbic acid derivative is equal to or greater than 1.5 mmol/L (mM). In a case where the medium contains two or more kinds of ascorbic acid derivatives, the aforementioned content of the ascorbic acid refers to the total content of the entire ascorbic acid derivatives contained in the medium. The medium according to the present invention can be preferably used as a medium for culture of pluripotent stem cells. 
     The ascorbic acid derivative is not particularly limited. However, the ascorbic acid derivative is preferably one kind of ascorbic acid derivative or two or more kinds of ascorbic acid derivatives selected from the group consisting of ascorbic acid, magnesium ascorbyl phosphate, sodium ascorbyl phosphate, aminopropyl ascorbyl phosphate, disodium ascorbyl sulfate, and ascorbyl 2-phosphoric acid ester, and more preferably magnesium ascorbyl phosphate. 
     The content of the ascorbic acid derivative in the medium according to the present invention is equal to or greater than 1.5 mmol/L, preferably equal to or greater than 1.6 mmol/L, more preferably equal to or greater than 3.0 mmol/L, even more preferably equal to or greater than 3.5 mmol/L, and still more preferably equal to or greater than 3.7 mmol/L. The upper limit of the content is not particularly limited. However, the upper limit of the content of the ascorbic acid derivative is preferably equal to or less than 100 mmol/L, more preferably equal to or less than 80 mmol/L, and even more preferably equal to or less than 50 mmol/L. 
     Any of the values of the upper limit may be combined with any of the values of the lower limit. For example, the content of the ascorbic acid derivative is preferably 1.5 mmol/L to 100 mmol/L, more preferably 1.6 mmol/L to 80 mmol/L, even more preferably 3.0 mmol/L to 80 mmol/L, and still more preferably 3.5 mmol/L to 50 mmol/L. 
     In addition to the ascorbic acid derivative, various components that can be generally added for culture of pluripotent stem cells may be added to the medium according to the present invention. Such components can be appropriately selected according to the type of cells to be cultured. For example, as the components other than the ascorbic acid derivative, glucose, fetal bovine serum (FBS), human serum, or antibiotics (penicillin, streptomycin, and the like) may be added. In a case where serum is added to the medium, the concentration thereof can be appropriately changed according to the state of culture at that time. However, generally, the concentration of serum can be 10% (v/v). 
     The medium according to the present invention is preferably a medium containing, as the components other than the ascorbic acid derivative, water, a salt (an inorganic salt such as sodium, potassium, magnesium, or calcium and an organic salt such as sodium pyruvate), an amino acid (an essential amino acid and a nonessential amino acid), vitamin (L-ascorbic acid, riboflavin, biotin, cyanocobalamin, or the like), a trace elements (selenium, iron, zinc, copper, or the like), a carbon source (D-glucose or the like), FGF (basic fibroblast growth factor FGF-2 or the like), TGF-β, insulin, and trensferrin. From the viewpoint of efficiently growing the pluripotent stem cells in an undifferentiated state, a medium containing FGF is preferable, and a medium containing FGF and TGF-3 is more preferable. 
     The medium according to the present invention can also be prepared by using a known medium such as a commercially available medium and adding an ascorbic acid derivative thereto such that the content of the ascorbic acid derivative according to the present invention is achieved. Examples of commercially available media that can be used for preparing the medium according to the present invention include Essential 8, DMEM, MEM, F 12, DME, RPMI 1640, MCDB 104 and 199, MCDB 153, L 15, SkBM, a Basal medium, and the like. Among these, Essential 8 is preferable. 
     In the culture method of the present invention, it is preferable that the pluripotent stem cells are cultured in the absence of a heterogeneous animal-derived component. In this way, a likelihood of the intermixing of a heterogeneous animal-derived foreign substance can be eliminated with high accuracy. Examples of the culture of pluripotent stem cells in the absence of a heterogeneous cell-derived component include the culture using a medium not containing a heterogeneous animal-derived component, the culture not using a heterogeneous animal-derived feeder cells, and the like. 
     Furthermore, in the culture method of the present invention, it is preferable that the pluripotent stem cells are cultured in the absence of a heterogeneous animal-derived component and a serum component. In this way, the intermixing of a heterogeneous animal-derived component can be more reliably prevented. 
     The medium according to the present invention may also be prepared by using, as a medium not containing the heterogeneous anima-derived component, a medium mixture composed of a hypoosmotic medium containing at least one kind of medium component such as a nonessential amino acid, glutamic acid, β-mercaptoethanol, FGF-2, TGF-β, insulin, or transferrin, and adding an ascorbic acid derivative thereto such that the content of an ascorbic acid derivative of the present invention is achieved. Specifically, the medium according to the present invention may be prepared by using a medium such as TeSR2 (Stemcell Technologies Inc) and adding an ascorbic acid derivative thereto such that the content of an ascorbic acid derivative of the present invention is achieved. However, the present invention is not limited to the above method. 
     The cells are cultured in an incubator under general culture conditions, for example, a temperature of 37° C. and a CO 2  concentration of 5% (v/v). 
     In the culture method and subculture method for pluripotent stem cells, the medium according to the present invention may be prepared by using a general medium, which is used for retaining pluripotent stem cells, and adding an ascorbic acid derivative thereto such that the content of an ascorbic acid derivative of the present invention is achieved. Specifically, for example, the medium according to the present invention may be prepared by using mTeSR, TeSR2 (Stemcell Technologies Inc), or the like and adding an ascorbic acid derivative thereto such that the content of an ascorbic acid of the present invention is achieved. The pluripotent stem cells are seeded into the medium by a common method. Herein, it is not necessary to use the same medium for a series of passages, and as long as the pluripotent stem cells can be kept undifferentiated, different media may be used. 
     In the culture surface preparation step, the culture surface coated with the polypeptide for culture is prepared by applying a coating solution, which contains the polypeptide for culture in a predetermined amount, to a culture surface of a support. In this way, the culture surface can be coated with the polypeptide for culture. 
     The content of the polypeptide for culture in the coating solution varies with the type and the size of the culture surface to be coated. However, from the viewpoint of the adsorbability with respect to the culture surface, the content of the polypeptide for culture is preferably 1 pmol/cm 2  to 1,000 pmol/cm 2 , and more preferably 100 pmol/cm 2  to 300 pmol/cm 2 . An aqueous medium used for preparing the coating solution is not particularly limited, and examples thereof include a phosphate buffer solution, a tris-buffer solution, ultrapure water, and the like. 
     In the coating operation, after being applied, the coating solution is held as it is for a certain period of time, for example, for about 30 minutes to 24 hours. In this way, the culture surface can be coated with the polypeptide for culture without the need to perform a special treatment. 
     The culture step includes culturing pluripotent stem cells by seeding the pluripotent stem cells onto the culture surface coated with the polypeptide for culture. 
     The seeding density and the culture conditions of the pluripotent stem cells are not particularly limited, and generally used conditions can be used as they are. For example, the cells may be seeded at a seeding density of about 1×10 3  cells/cm 2  to 1×10 5  cells/cm 2  and cultured under the aforementioned culture and subculture conditions. Furthermore, a cell mass with a diameter of 10 μm to 100 μm may be seeded at a seeding density of about 1 cell/cm 2  to 5 cells/cm 2  and cultured under the aforementioned culture and subculture conditions. 
     In this way, it is possible to excellently grow the pluripotent stem cells with excellent handleability on the polypeptide. Furthermore, in a case where the polypeptide (d) is used, it is possible to excellently grow the pluripotent stem cells while maintaining the undifferentiated state. 
     &lt;Culture Vessel&gt; 
     In the present invention, a culture vessel means a vessel having a support which has a surface used for cell culture. As the support, those known as a support for cell culture in the related art can be used as they are. Examples of the support may include plastic (for example, polystyrene, an acrylonitrile-butadiene-styrene resin, a polycarbonate resin, and a polyester resin), glass, filter with fine pores (for example, cellulose, nylon, glass fiber, polyester, and polycarbonate), a material for a bioreactor (may include hollow fiber tubes or microcarrier beads) used in batch cell culture, continuous cell culture, or genetic engineering (for example, a bioreactor), polyethylene terephthalate, Teflon (registered trademark), ceramic and polymer materials relating thereto, and the like. 
     In addition, the aforementioned support may be a support of which the culture surface is coated with a plasma-polymerized thin film. 
     The shape of the support is not particularly limited, and the support may have any shape as long as it is applicable to the culture of pluripotent stem cells. Examples of vessels with such a shape include a multi-well plate (for example, a 6-well plate, a 12-well plate, a 24-well plate, and a 96-well plate), a culture dish (for example, a petri dish), a tube, a culture flask, a roller bottle, a flask for shake culture, and the like. 
     The culture vessel according to the present invention includes a support having a cell culture surface and the polypeptide for culture disposed on the cell culture surface of the support. 
     The culture vessel of the present invention has the culture surface including the aforementioned polypeptide for culture according to the present invention. Therefore, the polypeptide for culture is excellently adsorbed onto the culture surface, and in a case where pluripotent stem cells are seeded onto the polypeptide for culture, the pluripotent stem cells with excellent handleability can grow in a state of being kept undifferentiated. 
     Herein, the culture surface in the culture vessel means a surface to which cells can adhere at the time of seeding and growing the cells. 
     The culture vessel according to the present invention can be manufactured by a manufacturing method including preparing a vessel with a support having a cell culture surface (hereinafter, referred to as a “preparation step”) and performing an adsorption treatment on the cell culture surface by applying the polypeptide for culture thereto (hereinafter, referred to as a “adsorption treatment step”). In this way, the culture vessel according to the present invention can be obtained in a simple manner. 
     In the preparation step, the culture vessel with the support having the culture surface is prepared. In a case where the support has a plasma-polymerized thin film on the culture surface, the preparation step may include a step of forming the plasma-polymerized thin film on the support. As the method for forming the plasma-polymerized thin film, a common method may be used as it is. 
     The adsorption treatment step includes applying the polypeptide for culture according to the present invention to the culture surface and holding the culture surface as it is. In the adsorption treatment step, the polypeptide for culture should be adsorbed onto the culture surface by preparing an adsorbent solution containing the polypeptide for culture in a predetermined amount, applying the adsorbent solution to the culture surface, and holding the culture surface as it is for a predetermined time. 
     In the adsorption treatment step, the details described in the step of preparing the culture surface coated with the polypeptide for culture in the culture method can be applied as they are. 
     &lt;Kit&gt; 
     The kit for culture of pluripotent stem cells of the present invention is a kit including (a) a polypeptide having an amino acid sequence represented by SEQ ID NO: 1, (b) a polypeptide having an amino acid sequence, which shares identity of equal to or higher than 80% with the polypeptide represented by SEQ ID NO: 1, and having culture performance for pluripotent stem cells, or (c) a polypeptide having an amino acid sequence, which is formed by the deletion, substitution, or addition of one amino acid or several amino acids (preferably 1 to 5 amino acids) in SEQ ID NO: 1, and having culture performance for pluripotent stem cells and a medium in which the content of an ascorbic acid derivative is equal to or greater than 1.5 mmol/L (mM). 
     Herein, the preferred ranges of all of the polypeptides (a) to (c), the type of the ascorbic acid derivative, the content of the ascorbic acid derivative, and other components of the medium are as described above. 
     Furthermore, another kit for culture of pluripotent stem cells of the present invention is a kit including a polypeptide and a medium in which the content of an ascorbic acid derivative is equal to or greater than 1.5 mmol/L (mM), in which the polypeptide is (d) a polypeptide consisting of 40 to 450 amino acid residues and including (1) a first region including at least one amino acid sequence selected from the group consisting of an amino acid sequence represented by CSYYQSC (SEQ ID NO: 2) and an amino acid sequence represented by RGD and (2) a second region including (2-i) an amino acid sequence which is represented by PRPSLAKKQRFRHRNRKGYRSQRGHSRGRNQN (SEQ ID NO: 3), (2-ii) an amino acid sequence which shares identity of equal to or higher than 80% with the amino acid sequence represented by SEQ ID NO: 3 and exhibits adsorbability with respect to a cell culture surface of a support, or (2-iii) an amino acid sequence which is formed by the deletion, substitution, or addition of one amino acid residue or several amino acid residues (preferably 1 to 5 amino acid residues) in the amino acid sequence represented by SEQ ID NO: 3 and exhibits adsorbability with respect to the cell culture surface of the support. 
     Herein, the preferred ranges of all of the polypeptide (d), the type of the ascorbic acid derivative, the content of the ascorbic acid derivative, and other components of the medium are as described above. 
     The medium of the present invention is a medium in which the content of an ascorbic acid derivative is equal to or greater than 1.5 mmol/L (mM). 
     Herein, the preferred ranges of all of the type of the ascorbic acid derivative, the content of the ascorbic acid derivative, and other components of the medium are as described above. 
     EXAMPLES 
     Hereinafter, the present invention will be specifically described based on examples, but the present invention is not limited thereto. Herein, unless otherwise specified, “%” is based on mass. 
     Reference Example 1 
     Preparation of Polypeptide 
     By a common method using PCR, gene sequences encoding each of the polypeptides RCP-1 to RCP-17 having the amino acid sequences shown in Tables 2 and 3 were amplified. Herein, RCP-11 corresponds to the sequence of natural human vitronectin. In Tables 2 and 3, the column of “NOTE” shows the position in the amino acid sequence (SEQ ID NO: 1) of natural human vitronectin corresponding to the amino acid sequence of each of the polypeptides. Here, in some cases, the amino acid sequence of each of the polypeptides include an amino acid sequence which is formed by the addition, deletion, or substitution occurring in the amino acid sequence of the natural human vitronectin within a range corresponding described in the tables. The amino acid sequences of RCP-1 to RCP-10 and RCP-17 are the same as each other, except that methionine is on the N-terminal in each of the amino acid sequences represented by SEQ ID NO: 4 to SEQ ID NO: 13 and SEQ ID NO: 38. 
     For RCP-1 to RCP-10 and RCP-17, target genes were inserted into pET-28b(+), which was cleaved in advance by being treated with NcoI (TAKARA BIO INC.), by using an InFusion Advantage PCR Cloning Kit (Clontech Laboratories, Inc), thereby constructing the respective expression vectors. For RCP-11 to RCP-16, target genes were inserted into pGEX-6P-1 (GE Healthcare Corporation), which was cleaved in advance by being treated with BamHI (TAKARA BIO INC.), in the same manner as described above, thereby constructing the respective expression vectors. The sequences of the expression vectors were checked by sequence analysis. 
     
       
         
           
               
               
               
               
             
               
                 TABLE 2 
               
               
                   
               
               
                   
                   
                 SEQ ID 
                   
               
               
                   
                 Amino acid sequence 
                 No. 
                 NOTE 
               
               
                   
               
             
            
               
                 RCP-1 
                 
                   
                     
                     
                         
                         
                     
                   
                 
                 14 
                 1-55 269-459 
               
               
                   
                 
                   
                     
                     
                         
                         
                     
                   
                 
                   
                   
               
               
                   
                 
                   
                     
                     
                         
                         
                     
                   
                 
                   
                   
               
               
                   
                 
                   
                     
                     
                         
                         
                     
                   
                 
                   
                   
               
               
                   
                 
                   
                     
                     
                         
                         
                     
                   
                 
                   
                   
               
               
                 RCP-2 
                 
                   
                     
                     
                         
                         
                     
                   
                 
                 15 
                 1-55 342-373 
               
               
                   
                 
                   
                     
                     
                         
                         
                     
                   
                 
                   
                   
               
               
                 RCP-3 
                 
                   
                     
                     
                         
                         
                     
                   
                 
                 16 
                 1-55 322-341 
               
               
                   
                 
                   
                     
                     
                         
                         
                     
                   
                 
                   
                 342-373 
               
               
                 RCP-4 
                 
                   
                     
                     
                         
                         
                     
                   
                 
                 17 
                 1-55 312-341 
               
               
                   
                 
                   
                     
                     
                         
                         
                     
                   
                 
                   
                 342-373 
               
               
                 RCP-5 
                 
                   
                     
                     
                         
                         
                     
                   
                 
                 18 
                 1-55 302-341 
               
               
                   
                 
                   
                     
                     
                         
                         
                     
                   
                 
                   
                 342-373 
               
               
                   
                 
                   
                     
                     
                         
                         
                     
                   
                 
                   
                   
               
               
                 RCP-6 
                 
                   
                     
                     
                         
                         
                     
                   
                 
                 19 
                 1-55 269-459 
               
               
                   
                 
                   
                     
                     
                         
                         
                     
                   
                 
                   
                 C274S 
               
               
                   
                 
                   
                     
                     
                         
                         
                     
                   
                 
                   
                   
               
               
                   
                 
                   
                     
                     
                         
                         
                     
                   
                 
                   
                   
               
               
                   
                 
                   
                     
                     
                         
                         
                     
                   
                 
                   
                   
               
               
                 RCP-7 
                 
                   
                     
                     
                         
                         
                     
                   
                 
                 20 
                 1-55 269-373 
               
               
                   
                 
                   
                     
                     
                         
                         
                     
                   
                 
                   
                 C274S 
               
               
                   
                 
                   
                     
                     
                         
                         
                     
                   
                 
                   
                   
               
               
                 RCP-8 
                 
                   
                     
                     
                         
                         
                     
                   
                 
                 21 
                 1-55 269-373 
               
               
                   
                 
                   
                     
                     
                         
                         
                     
                   
                 
                   
                 374-379 C274S 
               
               
                   
                 
                   
                     
                     
                         
                         
                     
                   
                 
                   
                   
               
               
                 RCP-9 
                 
                   
                     
                     
                         
                         
                     
                   
                 
                 22 
                 1-55 269-373 
               
               
                   
                 
                   
                     
                     
                         
                         
                     
                   
                 
                   
                 374-389 C274S 
               
               
                   
                 
                   
                     
                     
                         
                         
                     
                   
                 
                   
                   
               
               
                 RCP-10 
                 
                   
                     
                     
                         
                         
                     
                   
                 
                 23 
                 1-55 269-373 
               
               
                   
                 
                   
                     
                     
                         
                         
                     
                   
                 
                   
                 374-399 C274S 
               
               
                   
                 
                   
                     
                     
                         
                         
                     
                   
                 
                   
                   
               
               
                   
                 
                   
                     
                     
                         
                         
                     
                   
                 
                   
                   
               
               
                 RCP-17 
                 
                   
                     
                     
                         
                         
                     
                   
                 
                 39 
                 1-55 269-277 
               
               
                   
                 
                   
                     
                     
                         
                         
                     
                   
                 
                   
                 295-341 342-373 
               
               
                   
                 
                   
                     
                     
                         
                         
                     
                   
                 
                   
                 C274S 
               
               
                   
               
            
           
         
       
     
     
       
         
           
               
               
               
               
             
               
                 TABLE 3 
               
               
                   
               
             
            
               
                 RCP-11 
                 
                   
                     
                     
                         
                         
                     
                   
                 
                 24 
                 1-459 
               
               
                   
                 
                   
                     
                     
                         
                         
                     
                   
                 
                   
                   
               
               
                   
                 
                   
                     
                     
                         
                         
                     
                   
                 
                   
                   
               
               
                   
                 
                   
                     
                     
                         
                         
                     
                   
                 
                   
                   
               
               
                   
                 
                   
                     
                     
                         
                         
                     
                   
                 
                   
                   
               
               
                   
                 
                   
                     
                     
                         
                         
                     
                   
                 
                   
                   
               
               
                   
                 
                   
                     
                     
                         
                         
                     
                   
                 
                   
                   
               
               
                   
                 
                   
                     
                     
                         
                         
                     
                   
                 
                   
                   
               
               
                 RCP-12 
                 
                   
                     
                     
                         
                         
                     
                   
                 
                 25 
                 1-55 56-268 
               
               
                   
                 
                   
                     
                     
                         
                         
                     
                   
                 
                   
                   
               
               
                   
                 
                   
                     
                     
                         
                         
                     
                   
                 
                   
                   
               
               
                   
                 
                   
                     
                     
                         
                         
                     
                   
                 
                   
                   
               
               
                   
                 
                   
                     
                     
                         
                         
                     
                   
                 
                   
                   
               
               
                 RCP-13 
                 
                   
                     
                     
                         
                         
                     
                   
                 
                 26 
                 1-55 56-129 
               
               
                   
                 
                   
                     
                     
                         
                         
                     
                   
                 
                   
                   
               
               
                   
                 
                   
                     
                     
                         
                         
                     
                   
                 
                   
                   
               
               
                 RCP-14 
                 
                   
                     
                     
                         
                         
                     
                   
                 
                 27 
                 1-55 
               
               
                 RCP-15 
                 
                   
                     
                     
                         
                         
                     
                   
                 
                 28 
                 56-459 
               
               
                   
                 
                   
                     
                     
                         
                         
                     
                   
                 
                   
                   
               
               
                   
                 
                   
                     
                     
                         
                         
                     
                   
                 
                   
                   
               
               
                   
                 
                   
                     
                     
                         
                         
                     
                   
                 
                   
                   
               
               
                   
                 
                   
                     
                     
                         
                         
                     
                   
                 
                   
                   
               
               
                   
                 
                   
                     
                     
                         
                         
                     
                   
                 
                   
                   
               
               
                   
                 
                   
                     
                     
                         
                         
                     
                   
                 
                   
                   
               
               
                 RCP-16 
                 
                   
                     
                     
                         
                         
                     
                   
                 
                 29 
                 269-459 
               
               
                   
                 
                   
                     
                     
                         
                         
                     
                   
                 
                   
                   
               
               
                   
                 
                   
                     
                     
                         
                         
                     
                   
                 
                   
                   
               
               
                   
                 
                   
                     
                     
                         
                         
                     
                   
                 
               
               
                   
               
            
           
         
       
     
     The prepared expression vectors of RCP-1 to RCP-10 and RCP-17 were transformed into BL21(DE3)pLysS (Novagen) by a common method, applied to a kanamycin-containing LB plate, and incubated for 16 hours at 37° C. By a colony direct PCR method, the state where the vectors were introduced into the cells was checked. Thereafter, 1 mM IPTG (Wako Pure Chemical Industries, Ltd.) was added thereto, and the cells were cultured by being shaken for 5 hours at 37° C., thereby inducing the expression of the polypeptides. 
     The bacterial cells were collected through a centrifugal treatment and resuspended in a washing buffer (20 mM Tris, 150 mM NaCl, pH 7.6). Through sonication, the bacterial cells were fragmented and then subjected to centrifugation for 30 minutes at 4° C. and 15,000 rpm, and an insoluble fraction was collected. The bacterial cells were washed with a washing buffer containing 0.5% by mass of Triton x100, then resuspended in a low-concentration urea buffer (Low Urea Buffer: 20 mM Tris, 150 mM NaCl, 2 M urea, pH 7.6), and subjected to a sonication treatment. Through a centrifugation treatment, an insoluble fraction was collected, a high-concentration urea buffer (High Urea Buffer: 20 mM Tris, 150 mM NaCl, 8 M urea, pH 7.6) was then added thereto, and the insoluble fraction was solubilized through a sonification treatment. 
     The solution obtained by the method described above that contained a target peptide was purified by using AKTA Explorer 100 (GE Healthcare Corporation) and HiTrap Heparin HP 5 ml (GE Healthcare Corporation). By performing stepwise elution using a high-concentration urea buffer as a binding buffer and a high-salt concentration adjusting buffer (20 mM Tris, 1 M NaCl, 8 M urea, pH 7.6) as an elution buffer, the target polypeptide was purified. 
     The expression vectors of RCP-11 to RCP-16 prepared as above were transformed into BL21 (Novagen) by a common method, applied to an ampicillin-containing LB plate, and incubated for 16 hours at 37° C. By a colony direct PCR method, the state where the vectors were introduced into the cells was checked. Thereafter, 100 μM isopropyl-β-D-thiogalactopyranoside (IPTG) was added thereto, and the cells were cultured by being shaken for 24 hours at 20° C., thereby inducing the expression of the polypeptides. 
     The bacterial cells were collected, resuspended in a B-PER (registered trademark) Bacterial Protein Extraction Reagent in Phosphate Buffer (Thermo Fisher Scientific Inc.), and then fragmented through sonication. By performing centrifugation for 30 minutes at 4° C. and 15,000 rpm, an insoluble fraction was removed, and the supernatant was purified by using AKTA Explorer 100 and GSTrap HP 5 ml×2 (GE Healthcare Corporation). The eluted fraction was desalted by using Hiprep 26/10 Desalting (GE Healthcare Corporation). Furthermore, a protease (PreScission Protease) for cleaving a GST fusion protein was added thereto in a solution amount of 1/2,000, and the resultant was incubated for 24 hours at 4° C., thereby cleaving the GST tag. The resultant was purified again by using GSTrap HP 5 ml×2, and the cleaved GST tag was removed by being adsorbed onto a column. The fraction passing through the column was dialyzed using Slide-A-Lizer (3.5 K MWCO.: Thermo Fisher Scientific Inc., the same device will be used hereinafter) and substituted with PBS. 
     The polypeptide of RCP-1 obtained as above was subjected to electrophoresis by using Ready Gel (12.5%, Bio-Rad Laboratories, Inc.) and stained with a GelCode™ Blue Stain Reagent (Thermo Scientific). As a result, a single band could be confirmed at a site corresponding to a molecular weight of 28.3 kDa expected from the amino acid sequence. The same results were obtained from other polypeptides. 
     For RCP-1 to RCP-10 and RCP-17, each of the purified polypeptide solutions was dialyzed using Slide-A-Lizer (3.5 K MWCO.). Basically, by using a dialysis buffer (PBS, 1.5 M NaCl, 0.5 M L-arginine, 1 mM EDTA, pH 7.4) as an outer dialysate, urea was removed by stepwise dialysis. The concentration of the end-product of dialysis was calculated from the absorbence at 280 nm by using NanoDrop (Thermo Fisher Scientific Inc.). Table 4 shows whether or not aggregation occurred after dialysis. 
     Furthermore, the indices of hydrophobicity determined for each of the amino acids were summed up, the obtained value was divided by the number of the amino acids, and the outcome was determined as the GRAVY value (see Kyte J., Doolittle R. F. (1982), J. Mol. Biol, 157: 105-132). The GRAVY value is an index of the hydrophilicity and hydrophobicity of a polypeptide calculated from the degree of hydrophobicity of the amino acids contained in each polypeptide. The greater the GRAVY value, the more the polypeptide is hydrophobic, and the smaller the GRAVY value, the more the polypeptide is hydrophilic. The results are shown in Table 4. 
     Whether or not aggregation was occurred was evaluated based on the scale of G, A, and B as shown below. The results are summarized in Table 4. 
     G: The formation of an aggregate was not observed. 
     A: The formation of particles having a particle size of about 100 nm was observed. 
     B: The formation of an aggregation of particles having a particle size of equal to or greater than 1 mm was visually observed. 
     
       
         
           
               
               
               
               
             
               
                   
                 TABLE 4 
               
               
                   
                   
               
               
                   
                   
                 Number of amino 
                   
               
               
                   
                 GRAVY 
                 acids 
                 Aggregation 
               
               
                   
                   
               
             
            
               
                   
               
            
           
           
               
               
               
               
               
            
               
                   
                 RCP-1 
                 −0.835 
                 247 
                 A 
               
               
                   
                 RCP-2 
                 −1.516 
                 88 
                 G 
               
               
                   
                 RCP-3 
                 −1.124 
                 108 
                 G 
               
               
                   
                 RCP-4 
                 −1.150 
                 118 
                 G 
               
               
                   
                 RCP-5 
                 −1.124 
                 128 
                 G 
               
               
                   
                 RCP-6 
                 −0.875 
                 246 
                 A 
               
               
                   
                 RCP-7 
                 −0.979 
                 160 
                 A 
               
               
                   
                 RCP-8 
                 −1.045 
                 166 
                 A 
               
               
                   
                 RCP-9 
                 −0.958 
                 176 
                 B 
               
               
                   
                 RCP-10 
                 −0.971 
                 186 
                 B 
               
               
                   
                 RCP-17 
                 −1.072 
                 143 
                 A 
               
               
                   
                   
               
            
           
         
       
     
     From Table 4, it is understood that although each of RCP-2 to RCP-5, RCP-7, RCP-8, and RCP-17 is a polypeptide consisting of about 80 to 170 amino acid residues, and aggregation easily occurs in the polypeptide, the occurrence of aggregation is inhibited because the GRAVY value thereof is within a range of −1.70 to −0.975. 
     Reference Example 2 
     Evaluation of Adsorbability with Respect to Culture Dish 
     Each of the polypeptides obtained as above was diluted with a predetermined buffer such that they could be added to wells at a predetermined final concentration of 0 pmol/cm 2  to 200 pmol/cm 2 . Thereafter, each of the polypeptides was added in an amount of 64 μL to a plasma-treated 96-well plate made of polystyrene (Tissue Culture-Treated, Falcon). Each of the polypeptides was allowed to adsorb onto the plate by being incubated for 2 hours at 37° C., and then the wells were washed twice with PBS, thereby obtaining surfaces coated with each of the polypeptides of RCP-1 to RCP-16. 
     Among the surfaces coated with each of the polypeptides obtained as above, the surfaces coated with RCP-1 and RCP-11 to RCP-16 were applied with 64 μL of a borate buffer and 64 μL of 1 N NaOH, followed by incubation for 24 hours at 80° C. and 100% humidity. After the resultant was air-cooled, 75 μL of a borate buffer was added to each well, and 50 μL of a reaction solution obtained by mixing OPA (o-phthalaldehyde: Wako Pure Chemical Industries, Ltd./methanol solution (160 mg/ml)) with N-acetyl-L-cysteine (NAC: Wako Pure Chemical Industries, Ltd.)/borate buffer solution (2 mg/ml) at a ratio of 1:100 (mass ratio) was further added thereto. After incubation for 30 minutes at 40° C., the fluorescence intensity thereof was measured by using an Envision Multilabel Counter (PerkinElmer Inc.) (excitation 355 nm/fluorescence 486 nm). A calibration curve was separately prepared from each of the polypeptide solutions so as to calculate the amount of the polypeptide adsorbed. The results are shown in  FIG. 1 . In  FIG. 1 , a black rhombus indicates RCP-1, a black square indicates RCP-11, a black triangle indicates RCP-12, a black circle indicates RCP-13, a white rhombus indicates RCP-14, a white square indicates RCP-15, and a white triangle indicates RCP-16. 
     From  FIG. 1 , it is understood that among the polypeptides used in the test, the polypeptides of RCP-1, RCP-15, and RCP-16 including PRPSLAKKQRFRHRNRKGYRSQRGHSRGRNQN (SEQ ID NO: 3 [the 342 nd  to 373 rd  amino acid residues in SEQ ID NO: 1]) exhibits excellent adsorbability with respect to the plate that is equivalent to the adsorbability of RCP-11 having the sequence of human vitronectin. It is also understood that, in contrast, the amount of RCP-13 and RCP-14 not including PRPSLAKKQRFRHRNRKGYRSQRGHSRGRNQN adsorbed onto the plate is small and about 1/4 of the amount of the polypeptide including the aforementioned sequence adsorbed onto the plate, and thus RCP-13 and RCP-14 are inappropriate as materials to be adsorbed onto the culture dish. 
     Reference Example 3 
     Cell Adhesiveness Evaluation 1 
     The cell adhesiveness of human iPS cells (“Tic”: Cell No. JCRB 1331: from National Institute of Biomedical Innovation. [567-0085, 7-6-8 Asagi Saito Ibaraki-City Osaka]) with respect to the aforementioned polypeptides was evaluated in the following manner. 
     As feeder cells for retaining the human iPS cells, EmbryoMax (registered trademark) (early mouse embryonic fibroblasts: resistant to hygromycin, treated with mitomycin C, derived from C57/BL6, third passage) (Millipore Corporation) was used. By using DMEM (Invitrogen) and a 10% (v/v) fetal bovine serum medium, the feeder cells were cultured for 24 hours and attached to a T25 flask (Corning Incorporated). As a medium for the human iPS cells, the one obtained by adding FGF-2 (Sigma-Aldrich Co, LLC.) to a medium composed as shown in Table 5 at a final concentration of 10 ng/ml was used. 
     
       
         
           
               
               
               
             
               
                 TABLE 5 
               
               
                   
               
               
                 Composition 
                 Manufacturer 
                 Amount 
               
               
                   
               
             
            
               
                   
               
            
           
           
               
               
               
               
            
               
                 KO-DMEM/F12 
                 Invitrogen 
                 400 
                 ml 
               
               
                 Non-Essential Amino 
                   
                 4 
                 ml 
               
               
                 Acid Solution 
               
               
                 L-Glutamine 
                   
                 5 
                 ml 
               
               
                 Knock Out Serum Replacement 
                   
                 100 
                 ml 
               
               
                 2-mercaptoethanol 55 mM 
                 Wako Pure Chemical 
                 0.925 
                 ml 
               
               
                   
                 Industries, Ltd. 
               
               
                   
               
               
                 Total amount: about 500 ml 
               
            
           
         
       
     
     By using the aforementioned medium, the human iPS cells were retained and cultured in a 5% (v/v, the same unit will be used hereinafter) CO 2  incubator at 37° C. Except for the day after the seeding of the iPS cells, the medium was replaced every day. The subculture operation was performed by exfoliating the cells by using Dispase II (neutral protease Grade II, Roche) and separating the cells in an appropriate size by a pipetting operation. 
     The iPS cells cultured as described above were treated with TrypLE Select (Invitrogen) for 5 minutes at 37° C. and separated into a single cell. After being subjected to centrifugation for 2 minutes at 300 rpm, the cells were collected and suspended in TeSR2 (a medium not containing a heterogeneous animal-derived component and a serum component, STEMCELL Technologies.) containing Y-27362 ((R)-(+)-trans-N-(4-pyridyl)-4-(1-aminoethyl)-cyclohexanecarboxamide.2HCl.H 2 O, an Rho binding kinase inhibitor, Wako Pure Chemical Industries, Ltd.) at a final concentration of 10 μM. 
     Samples 1 to 17 were prepared to which each of RCP-1 to RCP-10, RCP-17, RCP-11, RCP-15, RCP-16, and control including human vitronectin (extracted from human serum, BD Biosciences) and recombinant laminin (rLaminin-5: Oriental Yeast Co., ltd. and Human Recombinant Laminin-511: BIOLAMINA AB) was added at the concentration shown in Table 6. The samples were added to the respective wells of a 96-well plate and adsorbed onto the plate by being held for 2 hours at 37° C. Into the respective wells of the 96-well plate treated with the peptides, iPS cells were seeded at a cell density of 30,000 cells/well. After the cells were cultured for 24 hours, the nonadhesive cells were washed off with PBS, and only the adhesive cells were immobilized by using 4% paraformaldehyde (Wako Pure Chemical Industries, Ltd.). By using an Attophos (registered trademark) AP Fluorescent Substrate System (Promega Corporation), the ALP activity was calculated, and from the calibration curve, the number of undifferentiated iPS cells having the ALP activity was calculated. The results are shown in Table 6. In Table 6, the cell adhesion rate is expressed as a relative value calculated by regarding the cell adhesion rate obtained from the sample 15 using natural vitronectin as being 100. n=3. 
     
       
         
           
               
               
               
               
             
               
                   
                 TABLE 6 
               
               
                   
                   
               
               
                   
                   
                   
                 Cell adhesion rate 
               
               
                   
                 Type of peptide 
                 Added amount 
                 (%) 
               
               
                   
                   
               
             
            
               
                   
               
            
           
           
               
               
               
               
               
            
               
                 Sample 1 
                 RCP-1 
                 200 
                 pmol/cm 2   
                 109.3 ± 5.3  
               
               
                 Sample 2 
                 RCP-2 
                 20 
                 μg/cm 2   
                 98.7 ± 6.2 
               
               
                 Sample 3 
                 RCP-3 
                 20 
                 μg/cm 2   
                 106.1 ± 4.5  
               
               
                 Sample 4 
                 RCP-4 
                 20 
                 μg/cm 2   
                 100.1 ± 4.5  
               
               
                 Sample 5 
                 RCP-5 
                 10 
                 μg/cm 2   
                 94.1 ± 6.5 
               
               
                 Sample 6 
                 RCP-6 
                 20 
                 μg/cm 2   
                 92.8 ± 4.4 
               
               
                 Sample 7 
                 RCP-7 
                 5 
                 μg/cm 2   
                 88.6 ± 8.1 
               
               
                 Sample 8 
                 RCP-8 
                 5 
                 μg/cm 2   
                 89.2 ± 1.4 
               
               
                 Sample 9 
                 RCP-9 
                 20 
                 μg/cm 2   
                  95.5 ± 10.2 
               
               
                 Sample 10 
                 RCP-10 
                 20 
                 μg/cm 2   
                 93.0 ± 7.8 
               
               
                 Sample 11 
                 RCP-17 
                 5 
                 μg/cm 2   
                 95.9 ± 4.6 
               
               
                 Sample 12 
                 RCP-11 
                 200 
                 pmol/cm 2   
                 93.5 ± 7.9 
               
               
                 Sample 13 
                 RCP-15 
                 200 
                 pmol/cm 2   
                 13.2 ± 3.4 
               
               
                 Sample 14 
                 RCP-16 
                 200 
                 pmol/cm 2   
                  9.4 ± 2.9 
               
               
                 Sample 15 
                 Natural vitronectin 
                 130 
                 pmol/cm 2   
                 100 ± 5.5 
               
               
                 Sample 16 
                 rLaminin-5 
                 3.2 
                 μg/cm 2   
                 155.7 
               
               
                 Sample 17 
                 Laminin-511 
                 5.0 
                 μg/cm 2   
                 142.0 
               
               
                   
               
            
           
         
       
     
     As shown in Table 6, RCP-1 to RCP-10, PCR-17, and RCP-11, which had the 1 st  to 55 th  amino acids of the sequence represented by SEQ ID NO: 1, and natural human vitronectin were excellent in the cell adhesion rate of the iPS cells. Particularly, the cell adhesion rate was higher in RCP-1 to RCP-10 and PCR-17, which did not include a portion of the 56 th  to 268 th  amino acids of the sequence represented by SEQ ID NO: 1 or included none of the above amino acids, than in RCP-11 having the same amino acid sequence as the natural human vitronectin. Therefore, it is understood that a sequence important for the cell adhesion is present in the 1 st  to 55 th  amino acids of the sequence represented by SEQ ID NO: 1. 
     Reference Example 4 
     Cell Adhesiveness Evaluation 2 
     The polypeptides shown in Table 7 were synthesized by an Fmoc solid-phase synthesis method. A surface onto which natural vitronectin was adsorbed at a concentration of 130 pmol/cm 2  was prepared, and then a cell suspension to which 100 μM of the aforementioned synthetic polypeptides were added was seeded into wells at a ratio of 30,000 cells/well. The number of adhesive cells 24 hours after seeding was calculated in the same manner as in &lt;Cell adhesiveness evaluation 1&gt;, and the results are shown in Table 7. In Table 7, the cell adhesion rate is expressed as a relative value calculated by regarding the cell adhesion rate obtained by using a culture solution not containing the synthetic polypeptides as being 100%. n=3. 
     
       
         
           
               
               
               
               
             
               
                 TABLE 7 
               
               
                   
               
               
                   
                 Sequence of synthetic 
                 Cell adhesion 
                 SEQ 
               
               
                   
                 polypeptide 
                 rate (%) 
                 ID No 
               
               
                   
               
             
            
               
                 Peptide-1 
                 DQESCKGRCTEGFNVDKKCQ 
                 91.8 ± 1.2  
                 30 
               
               
                   
               
               
                 Peptide-2 
                 KGRCTEGFNVDKKCQCDELC 
                 92.7 ± 19.6 
                 31 
               
               
                   
               
               
                 Peptide-3 
                 EGFNVDKKCQCDELCSYYQS 
                 102.5 ± 4.2   
                 32 
               
               
                   
               
               
                 Peptide-4 
                 DKKCQCDELCSYYQSCCTDY 
                 63.8 ± 11.6 
                 33 
               
               
                   
               
               
                 Peptide-5 
                 CCTDYTAECKPQVTRGDVFT 
                 70.5 ± 7.1  
                 34 
               
               
                   
               
               
                 Peptide-6 
                 TAECKPQVTRGDVFTMPEDE 
                 52.7 ± 10.3 
                 35 
               
               
                   
               
               
                 Peptide-7 
                 CCTDYTAECKPQVTRGEVFT 
                 86.7 ± 7.1  
                 36 
               
               
                   
               
               
                 Peptide-8 
                 TAECKPQVTRGEVFTMPEDE 
                 83.8 ± 14.8 
                 37 
               
               
                   
               
            
           
         
       
     
     From Table 7, it is understood that while the adhesion of cells to the natural vitronectin is significantly hindered by the addition of Peptides-4, 5, and 6 including CSYYQSC (SEQ ID NO: 2) or RGD, the adhesion of cells is not hindered by the addition of Peptides-1, 2, and 3 not including CSYYQSC and RGD and Peptides-7 and 8 obtained by substituting the RGD sequence of Peptides-5 and 6 with RGE. Accordingly, it is understood that the polypeptide exhibits cell adhesion ability, in a case where the polypeptide includes at least one of CSYYQSC and RGD. 
     Reference Example 5 
     Growth Evaluation 
     The iPS cells collected in the same manner as in &lt;Cell adhesiveness evaluation 1&gt; were seeded into a 96-well plate, onto which RCP-1, RCP-11, and natural human vitronectin were adsorbed, at a ratio of 250 cells/well and cultured for 8 days in a 5% CO 2  incubator at 37° C. The number of adhesive cells after different days of culture was measured in the same manner as in &lt;Cell adhesiveness evaluation 1&gt;, thereby obtaining growth curves.  FIG. 2  shows the growth curves. In  FIG. 2 , a black rhombus indicates a case using RCP-1, and a black square indicates a case using RCP-11. 
     By adding RCP-1 to RCP-10, RCP-17, and Human Recombinant Laminin-511 as control at the concentration shown in Table 8, samples 1 to 12 were prepared. The samples were seeded into a 96-well plate, onto which each of the polypeptides was adsorbed in the same manner as in &lt;Cell adhesiveness evaluation 1&gt;, at a ratio of 5,000 cells/well and cultured for 3 days in a CO 2  incubator at 37° C. The number of cells after 3 days was calculated in the same manner as in &lt;Cell adhesiveness evaluation 1&gt;. The results are shown in Table 8. 
     
       
         
           
               
               
               
               
             
               
                   
                 TABLE 8 
               
               
                   
                   
               
               
                   
                   
                   
                 Number of cells 
               
               
                   
                 Type of peptide 
                 Added amount 
                 after 3 days (%) 
               
               
                   
                   
               
             
            
               
                   
               
            
           
           
               
               
               
               
            
               
                 Sample 1 
                 RCP-1 
                 80 μg/cm 2   
                 100.0 
               
               
                 Sample 2 
                 RCP-2 
                 20 μg/cm 2   
                 81.7 
               
               
                 Sample 3 
                 RCP-3 
                 20 μg/cm 2   
                 109.7 
               
               
                 Sample 4 
                 RCP-4 
                 20 μg/cm 2   
                 120.7 
               
               
                 Sample 5 
                 RCP-5 
                 10 μg/cm 2   
                 121.2 
               
               
                 Sample 6 
                 RCP-6 
                 20 μg/cm 2   
                 70.5 
               
               
                 Sample 7 
                 RCP-7 
                  5 μg/cm 2   
                 89.9 
               
               
                 Sample 8 
                 RCP-8 
                  5 μg/cm 2   
                 171.0 
               
               
                 Sample 9 
                 RCP-9 
                 20 μg/cm 2   
                 105.8 
               
               
                 Sample 10 
                 RCP-10 
                 20 μg/cm 2   
                 101.9 
               
               
                 Sample 11 
                 RCP-17 
                  5 μg/cm 2   
                 153.5 
               
               
                 Sample 12 
                 Laminin-511 
                 1.28 μg/cm 2    
                 56.8 
               
               
                   
               
            
           
         
       
     
     As shown in  FIG. 2 , RCP-1 showed higher cell growth properties compared to RCP-11 having the amino acid sequence of the natural vitronectin, and on Day 8 of culture, the number of cells in the case using RCP-11 was about 1/3 of the number of cells in the case where RCP-1 was used. From the increase and decrease in the obtained number of cells, the doubling time was calculated. As a result, it was confirmed that it takes 46.4±2.1 hours for the number of cells to be doubled in a case where RCP-1 is used, and 67.7±2.1 hours in a case where RCP-11 is used. 
     From Table 8, it is understood that all of RCP-1 to RCP-10 and RCP-17 show a higher cell growth rate compared to laminin which is the extracellular matrix just like vitronectin. Furthermore, it is understood that even if the 274 th  cysteine residue in SEQ ID NO: 1 was substituted with a serine residue, the same high cell growth rate as described above is obtained. 
     From the results shown in  FIG. 2  and Table 8, it is understood that, surprisingly, RCP-1 to RCP-10 and RCP-17, which include a sequence effective for the cell growth and the adsorption onto the culture dish but do not include a sequence corresponding to a portion or the entirety of the 56 to 268 amino acids of natural human vitronectin, have a growth ability higher than that of RCP-11 having the same sequence as the human vitronectin and Laminin-511 as a comparative example. 
     Furthermore, from Table 8, it is understood that all of RCP-1 to RCP-10 and RCP-17 including both the sequences of CSYYQSC (SEQ ID NO: 2) and RDG and the sequence of PRPSLAKKQRFRHRNRKGYRSQRGHSRGRNQN (SEQ ID NO: 3) show high cell growth properties. 
     Reference Example 6 
     Cell Adhesiveness Evaluation 3 
     The cell adhesiveness was evaluated in the same manner as in &lt;Cell adhesiveness evaluation 1&gt;, except that RCP-1 was used after the concentration thereof was adjusted to 125 pmol/cm 2  to 1,000 pmol/cm 2  by using PBS. The results are shown in Table 9. In Table 9, the cell adhesion rate is expressed as relative value calculated by regarding a cell adhesion rate with respect to the culture vessel, onto which natural vitronectin is adsorbed at a concentration of 130 pmol/cm 2 , as being 100. n=3. 
     
       
         
           
               
               
               
               
             
               
                   
                 TABLE 9 
               
               
                   
                   
               
               
                   
                   
                   
                 Cell adhesion rate 
               
               
                   
                 Type of peptide 
                 Added amount 
                 (%) 
               
               
                   
                   
               
             
            
               
                   
                 RCP-1 
                 1000 pmol/cm 2   
                 98.5 ± 17.2 
               
               
                   
                 RCP-1 
                 500 pmol/cm 2   
                 108.8 ± 23.0  
               
               
                   
                 RCP-1 
                 250 pmol/cm 2   
                 89.2 ± 10.6 
               
               
                   
                 RCP-1 
                 125 pmol/cm 2   
                 90.3 ± 25.3 
               
               
                   
                 Natural vitronectin 
                 130 pmol/cm 2   
                 100 ± 5.5  
               
               
                   
                   
               
            
           
         
       
     
     As shown in Table 9, in a case where the amount of RCP-1 added was equal to or greater than 125 pmol/cm 2 , the adhesiveness of iPS cells with respect to RCP-1 was equivalent to the cell adhesion rate of the natural vitronection. 
     Reference Example 7 
     Evaluation of Maintenance of Undifferentiated State 
     iPS cells collected in the same manner as in &lt;Cell adhesiveness evaluation 1&gt; were suspended in TeSR2. The iPS cells were seeded into 6-well plate (Tissue culture-treated, Falcon), onto which each of the samples 1, 2, 5, 6, and 7 used in &lt;Cell adhesiveness evaluation 1&gt; was adsorbed in the same manner as in &lt;Cell adhesiveness evaluation 1&gt;, and cultured in a CO 2  incubator at 37° C. Except for the day after the seeding, the medium was replaced every day. In the same method as described above, the cells were subcultured every six days.  FIGS. 3A to 3E  show forms of the iPS cells cultured on each of the samples. 
     After being cultured for 1 month under the conditions described above, the cells were immobilized using 4% paraformaldehyde and treated with 1% Triton-X/PBS so as to enhance the membrane permeability. After the cells were subjected to a blocking treatment using an Image IT Signal Enhancer (Invitrogen), an anti-human NANOG antibody (AF 1997, R&amp;D Systems, Inc.), an Alexa Fluor 555 binding rabbit anti-goat IgG antibody (Invitrogen), and DAPI (Dojindo Molecular Technologies, Inc.) were added thereto for labeling, and the cells were imaged using a fluorescence microscope.  FIGS. 4A to 4E  show the fluorescence microscopic images. 
       FIGS. 3A and 4A  show the iPS cells cultured on RCP-1;  FIGS. 3B and 4B  show the iPS cells cultured on RCP-11;  FIGS. 3C and 4C  show the iPS cells cultured on natural human vitronectin;  FIGS. 3D and 4D  show the iPS cells cultured on rLaminin-5; and  FIGS. 3E and 4E  show the iPS cells cultured on rLaminin-511. The scale bar in the images indicates 100 μm. In  FIGS. 3A to 3E , the images on the left side are full images of the colony, and the images on the right side are magnified images. In  FIGS. 4A to 4E , the images on the left side are images of the cells stained with DAPI, and the images on the right side are images of the cells stained with an anti-NANOG antibody. The scale bar in  FIGS. 3 and 4  indicates 200 μm. 
     As shown in  FIGS. 3A to 3E , the iPS cells, which were cultured on RCP-1, RCP-11, and the natural human vitronectin including a sequence effective for the cell growth and the adsorption onto the culture dish, had a form specific to undifferentiated cells which have a homogeneous colony and posses nuclei at a high ratio. Furthermore, as shown in  FIGS. 4A to 4E , the iPS cells, which were cultured on RCP-1, RCP-11, and the natural human vitronectin having a cell growth domain and an adsorption domain, strongly expressed NANOG in the entirety of the colony, and accordingly, it was understood that the undifferentiated state is excellently maintained. 
     From the evaluation results of Reference examples 1 to 7, it was understood that the polypeptide, which includes either the sequence CSYYQSC (SEQ ID NO: 2) or the sequence RGD and the sequence of PRPSLAKKQRFRHRNRKGYRSQRGHSRGRNQN (SEQ ID NO: 3) and consists of 40 to 450 amino acid residues, is excellent in the adsorbability with respect to the cell culture surface of the support. Furthermore, it was understood that under the condition of co-culture with iPS cells, such a polypeptide is equivalent to RCP-11 having a sequence equivalent to that of the natural vitronectin and human vitronection, in terms of the cell adhesiveness of the iPS cell and the maintenance of the undifferentiated state, and is better than RCP-11 in terms of the growth properties of the iPS cells. It was also understood that all of RCP-1 to RCP-10 and RCP-17 are excellent in terms of the cell adhesiveness of the iPS cells and the maintenance of the undifferentiated state. Such excellent results in terms of the aforementioned abilities were not obtained from other polypeptides or the recombinant laminin as a comparative example. 
     Therefore, according to the polypeptide (d) of the present invention, it is possible to provide a polypeptide, which enables pluripotent stem cells to grow in an undifferentiated state and is excellent in the adsorbability with respect to the cell culture surface, and a culture method and a culture vessel for pluripotent stem cells using the polypeptide. 
     Examples 
     Growth Evaluation 
     The growth of cells was evaluated in the same manner as in Reference example 5. 
     Magnesium ascorbyl phosphate was added to a medium. Essential 8 (manufactured by Life Technologies), and RCP-17 and Human Recombinant Laminin-511 as control were added thereto such that the concentration of each of the polypeptides became as shown in Table 10, thereby preparing samples 1 to 15. The samples were adsorbed onto a 96-well plate, and the iPS cells collected in the same manner as in &lt;Cell adhesiveness evaluation 1&gt; were seeded into the plate at a ratio of 1×10 4  cells/well and cultured for 3 days in a 5% CO 2  incubator at 37° C. The number of cells after 3 days was measured in the same manner as in &lt;Cell adhesiveness evaluation 1&gt;. Furthermore, by using VTN-N (manufactured by Life Technologies) and Vitronectin-XF (manufactured by Primorigen Biosciences), the growth of the cells was evaluated in the same manner. 
     The results obtained from RCP-17 are shown in Table 10, the results obtained from Human Recombinant Laminin-511 are shown in Table 11, the results obtained from VTN-N (manufactured by Life Technologies) are shown in Table 12, and the results obtained from Vitronectin-XF (manufactured by Primorigen Biosciences) are shown in Table 13. In Tables 10 and 11, the number of cells is expressed as a relative value calculated by regarding the number of cells at the concentration of magnesium ascorbyl phosphate of 0.8 mmol/L as being 100. n=3. 
     
       
         
           
               
               
               
               
               
               
             
               
                 TABLE 10 
               
               
                   
               
               
                   
                   
                   
                   
                 Number 
                   
               
               
                   
                   
                   
                 Concentration 
                 of cells 
                   
               
               
                   
                   
                   
                 of magnesium 
                 after 
               
               
                 Sample 
                 Type of 
                 Added 
                 ascorbyl 
                 3 days 
               
               
                 No. 
                 peptide 
                 amount 
                 phosphate 
                 (%) 
                 Note 
               
               
                   
               
             
            
               
                   
               
            
           
           
               
               
               
               
               
               
            
               
                 1 
                 RCP-17 
                 100 μg/cm 3   
                 0.2 mmol/L 
                 114 
                 Comparative 
               
               
                   
                   
                   
                   
                   
                 example 
               
               
                 2 
                 RCP-17 
                 100 μg/cm 3   
                 0.5 mmol/L 
                 98 
                 Comparative 
               
               
                   
                   
                   
                   
                   
                 example 
               
               
                 3 
                 RCP-17 
                 100 μg/cm 3   
                 0.8 mmol/L 
                 100 
                 Comparative 
               
               
                   
                   
                   
                   
                   
                 example 
               
               
                 4 
                 RCP-17 
                 100 μg/cm 3   
                 1.6 mmol/L 
                 145 
                 Present 
               
               
                   
                   
                   
                   
                   
                 invention 
               
               
                 5 
                 RCP-17 
                 100 μg/cm 3   
                 3.7 mmol/L 
                 219 
                 Present 
               
               
                   
                   
                   
                   
                   
                 invention 
               
               
                 6 
                 RCP-17 
                 100 μg/cm 3   
                 9.1 mmol/L 
                 212 
                 Present 
               
               
                   
                   
                   
                   
                   
                 invention 
               
               
                 7 
                 RCP-17 
                 100 μg/cm 3   
                 18.1 mmol/L  
                 204 
                 Present 
               
               
                   
                   
                   
                   
                   
                 invention 
               
               
                 8 
                 RCP-17 
                 100 μg/cm 3   
                 36.0 mmol/L  
                 230 
                 Present 
               
               
                   
                   
                   
                   
                   
                 invention 
               
               
                   
               
            
           
         
       
     
     
       
         
           
               
               
               
               
               
               
             
               
                 TABLE 11 
               
               
                   
               
               
                   
                   
                   
                   
                 Number 
                   
               
               
                   
                   
                   
                 Concentration 
                 of cells 
                   
               
               
                 Sam- 
                   
                   
                 of magnesium 
                 after 
               
               
                 ple 
                 Type of 
                 Added 
                 ascorbyl 
                 3 days 
               
               
                 No. 
                 peptide 
                 amount 
                 phosphate 
                 (%) 
                 Note 
               
               
                   
               
             
            
               
                   
               
            
           
           
               
               
               
               
               
               
            
               
                 9 
                 Laminin-511 
                 20 μg/cm 3   
                 0.2 mmol/L 
                 61 
                 Comparative 
               
               
                   
                   
                   
                   
                   
                 example 
               
               
                 10 
                 Laminin-511 
                 20 μg/cm 3   
                 0.5 mmol/L 
                 79 
                 Comparative 
               
               
                   
                   
                   
                   
                   
                 example 
               
               
                 11 
                 Laminin-511 
                 20 μg/cm 3   
                 0.8 mmol/L 
                 100 
                 Comparative 
               
               
                   
                   
                   
                   
                   
                 example 
               
               
                 12 
                 Laminin-511 
                 20 μg/cm 3   
                 1.6 mmol/L 
                 90 
                 Comparative 
               
               
                   
                   
                   
                   
                   
                 example 
               
               
                 13 
                 Laminin-511 
                 20 μg/cm 3   
                 3.7 mmol/L 
                 114 
                 Comparative 
               
               
                   
                   
                   
                   
                   
                 example 
               
               
                 14 
                 Laminin-511 
                 20 μg/cm 3   
                 9.1 mmol/L 
                 100 
                 Comparative 
               
               
                   
                   
                   
                   
                   
                 example 
               
               
                 15 
                 Laminin-511 
                 20 μg/cm 3   
                 18.1 mmol/L  
                 112 
                 Comparative 
               
               
                   
                   
                   
                   
                   
                 example 
               
               
                   
               
            
           
         
       
     
     
       
         
           
               
               
               
               
               
               
             
               
                 TABLE 12 
               
               
                   
               
               
                   
                   
                   
                 Concentration 
                 Number of 
                   
               
               
                   
                   
                   
                 of magnesium 
                 cells after 
               
               
                 Sample 
                 Type of 
                 Added 
                 ascorbyl 
                 3 days 
               
               
                 No. 
                 peptide 
                 amount 
                 phosphate 
                 (%) 
                 Note 
               
               
                   
               
             
            
               
                 16 
                 VTN-N 
                 20 μg/cm 3   
                 0.2 mmol/L 
                 100 
                 Comparative 
               
               
                   
                   
                   
                   
                   
                 example 
               
               
                 17 
                 VTN-N 
                 20 μg/cm 3   
                 1.6 mmol/L 
                 121 
                 Example 
               
               
                 18 
                 VTN-N 
                 20 μg/cm 3   
                 3.7 mmol/L 
                 124 
                 Example 
               
               
                 19 
                 VTN-N 
                 20 μg/cm 3   
                 9.1 mmol/L 
                 132 
                 Example 
               
               
                 20 
                 VTN-N 
                 20 μg/cm 3   
                 18.1 mmol/L  
                 135 
                 Example 
               
               
                 21 
                 VTN-N 
                 20 μg/cm 3   
                 36.0 mmol/L  
                 149 
                 Example 
               
               
                   
               
            
           
         
       
     
     
       
         
           
               
               
               
               
               
               
             
               
                 TABLE 13 
               
               
                   
               
               
                   
                   
                   
                 Final 
                 Number 
                   
               
               
                   
                   
                   
                 concentration 
                 of cells 
               
               
                 Sam- 
                   
                   
                 of magnesium 
                 after 
               
               
                 ple 
                   
                 Added 
                 ascorbyl 
                 3 days 
               
               
                 No. 
                 Type of peptide 
                 amount 
                 phosphate 
                 (%) 
                 Note 
               
               
                   
               
             
            
               
                 22 
                 Vitronectin-XF 
                 10 μg/cm 3   
                 0.2 mmol/L 
                 100 
                 Com- 
               
               
                   
                   
                   
                   
                   
                 parative 
               
               
                   
                   
                   
                   
                   
                 example 
               
               
                 23 
                 Vitronectin-XF 
                 10 μg/cm 3   
                 1.6 mmol/L 
                 151 
                 Example 
               
               
                 24 
                 Vitronectin-XF 
                 10 μg/cm 3   
                 3.7 mmol/L 
                 153 
                 Example 
               
               
                 25 
                 Vitronectin-XF 
                 10 μg/cm 3   
                 9.1 mmol/L 
                 150 
                 Example 
               
               
                 26 
                 Vitronectin-XF 
                 10 μg/cm 3   
                 18.1 mmol/L  
                 155 
                 Example 
               
               
                 27 
                 Vitronectin-XF 
                 10 μg/cm 3   
                 36.0 mmol/L  
                 185 
                 Example 
               
               
                   
               
            
           
         
       
     
     From the results shown in Table 10, it was confirmed that in a case where the cells are cultured using RCP-17, the number of growing cells increases in Samples 4 to 8 depending on the concentration of magnesium ascorbyl phosphate, and there is a significant difference in the number of growing cells between the samples. In contrast, from the results shown in Table 11, it was confirmed that in a case where Human Recombinant Laminin-511 is used, the number of growing cells does not depend on the concentration of magnesium ascorbyl phosphate, and there is no significant difference in the number of growing cells between any two samples among the samples 9 to 15. From the results shown in Table 12, it was confirmed that in a case where VTN-N is used, the number of growing cells increases in the samples 17 to 21 depending on the concentration of magnesium ascorbyl phosphate, and there is a significant difference in the number of growing cells between the samples. From the results shown in Table 13, it was confirmed that in a case where Vitronectin-XF is used, the number of growing cells increases in the samples 23 to 27 depending on the concentration of magnesium ascorbyl phosphate, and there is a significant difference in the number of growing cells between the samples. 
     The entirety of the disclosure of JP2013-187441 filed on Sep. 10, 2013 is incorporated into the present specification by reference. 
     All of the documents, patent applications, and technical standards described in the present specification are incorporated into the present specification by reference as if each of the documents, patent applications, and technical standards is specifically and independently described so as to be incorporated into the present specification by reference.